<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        93-116-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZARZIO 48 mU/0.5 mL solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FILGRASTIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.48
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        725.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="IDT Biologika GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            IDT Biologika GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zarzio&nbsp;is a white blood cell growth factor (granulocyte colony stimulating factor) and belongs to a group&nbsp;of&nbsp;proteins&nbsp;called&nbsp;cytokines.&nbsp;Growth&nbsp;factors&nbsp;are&nbsp;proteins&nbsp;that&nbsp;are&nbsp;produced&nbsp;naturally&nbsp;in&nbsp;the&nbsp;body&nbsp;but&nbsp;they&nbsp;can&nbsp;also&nbsp;be&nbsp;made&nbsp;using&nbsp;biotechnology&nbsp;for&nbsp;use&nbsp;as&nbsp;a&nbsp;medicine.&nbsp;Zarzio&nbsp;works&nbsp;by&nbsp;encouraging&nbsp;the bone&nbsp;marrow&nbsp;to&nbsp;produce&nbsp;more&nbsp;white&nbsp;blood&nbsp;cells.&nbsp;</p><p>&nbsp;</p><p>A&nbsp;reduction&nbsp;in&nbsp;the&nbsp;number&nbsp;of&nbsp;white&nbsp;blood&nbsp;cells&nbsp;(neutropenia)&nbsp;can&nbsp;occur&nbsp;for&nbsp;several&nbsp;reasons&nbsp;and&nbsp;makes your body less able to fight infection.&nbsp;Zarzio&nbsp;stimulates the bone marrow to produce new white cells quickly.&nbsp;</p><p>&nbsp;</p><p>Zarzio&nbsp;can be used:&nbsp;</p><p>&nbsp;</p><ul><li><p>to&nbsp;increase&nbsp;the&nbsp;number&nbsp;of&nbsp;white&nbsp;blood&nbsp;cells&nbsp;after&nbsp;treatment&nbsp;with&nbsp;chemotherapy&nbsp;to&nbsp;help&nbsp;prevent&nbsp;infections;&nbsp;</p></li><li><p>to&nbsp;increase&nbsp;the&nbsp;number&nbsp;of&nbsp;white&nbsp;blood&nbsp;cells&nbsp;after&nbsp;a&nbsp;bone&nbsp;marrow&nbsp;transplant&nbsp;to&nbsp;help&nbsp;prevent&nbsp;infections;&nbsp;</p></li><li><p>before&nbsp;high-dose&nbsp;chemotherapy&nbsp;to&nbsp;make&nbsp;the&nbsp;bone&nbsp;marrow&nbsp;produce&nbsp;more&nbsp;stem&nbsp;cells&nbsp;which&nbsp;can&nbsp;be collected&nbsp;and&nbsp;given&nbsp;back&nbsp;to&nbsp;you&nbsp;after&nbsp;your&nbsp;treatment.&nbsp;These&nbsp;can&nbsp;be&nbsp;taken&nbsp;from&nbsp;you&nbsp;or&nbsp;from&nbsp;a&nbsp;donor.&nbsp;The&nbsp;stem&nbsp;cells&nbsp;will&nbsp;then&nbsp;go&nbsp;back&nbsp;into&nbsp;the&nbsp;bone&nbsp;marrow&nbsp;and&nbsp;produce&nbsp;blood&nbsp;cells;&nbsp;</p></li><li><p>to&nbsp;increase&nbsp;the&nbsp;number&nbsp;of&nbsp;white&nbsp;blood&nbsp;cells&nbsp;if&nbsp;you&nbsp;suffer&nbsp;from&nbsp;severe&nbsp;chronic&nbsp;neutropenia&nbsp;to&nbsp;help prevent&nbsp;infections;&nbsp;</p></li></ul><ul><li><p>in&nbsp;patients&nbsp;with&nbsp;advanced&nbsp;HIV&nbsp;infection&nbsp;which&nbsp;will&nbsp;help&nbsp;reduce&nbsp;the&nbsp;risk&nbsp;of&nbsp;infections.&nbsp;</p></li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use&nbsp;Zarzio&nbsp;</strong></p><p>- if&nbsp;you&nbsp;are&nbsp;allergic&nbsp;to&nbsp;filgrastim&nbsp;or&nbsp;any&nbsp;of&nbsp;the&nbsp;other&nbsp;ingredients&nbsp;of&nbsp;this&nbsp;medicine&nbsp;(listed&nbsp;in&nbsp;section&nbsp;6).&nbsp;</p><p><strong>Warnings and precautions&nbsp;</strong></p><p>Talk to your doctor, pharmacist or nurse before using&nbsp;Zarzio.&nbsp;</p><p>Take special care with&nbsp;Zarzio&nbsp;if you have ever had an allergic reaction to latex. Please tell your doctor before starting treatment&nbsp;if you have:&nbsp;</p><ul><li><p>osteoporosis&nbsp;(bonedisease);&nbsp;</p></li><li><p>sickle&nbsp;cell&nbsp;anaemia,&nbsp;as&nbsp;Zarzio&nbsp;may&nbsp;cause&nbsp;sickle&nbsp;cell&nbsp;crisis.&nbsp;</p></li></ul><p>&nbsp;</p><p>Please tell your doctor immediately during treatment with&nbsp;Zarzio, if you:&nbsp;</p><ul><li><p>get left upper belly (abdominal) pain, pain below the left rib cage or at the tip of your left shoulder&nbsp;[these&nbsp;may&nbsp;be&nbsp;symptoms&nbsp;of&nbsp;an&nbsp;enlarged&nbsp;spleen&nbsp;(splenomegaly),&nbsp;or&nbsp;possibly&nbsp;rupture&nbsp;of the&nbsp;spleen].&nbsp;</p></li><li><p>notice&nbsp;unusual&nbsp;bleeding&nbsp;or&nbsp;bruising&nbsp;[these&nbsp;may&nbsp;be&nbsp;symptoms&nbsp;of&nbsp;a&nbsp;decrease&nbsp;in&nbsp;blood&nbsp;platelets (thrombocytopenia),&nbsp;with&nbsp;a&nbsp;reduced&nbsp;ability&nbsp;of&nbsp;your&nbsp;blood&nbsp;to&nbsp;clot].&nbsp;</p></li><li><p>have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips,&nbsp;tongue&nbsp;or&nbsp;other&nbsp;parts&nbsp;of&nbsp;the&nbsp;body,&nbsp;shortness&nbsp;of&nbsp;breath,&nbsp;wheezing&nbsp;or&nbsp;trouble&nbsp;breathing&nbsp;as these&nbsp;could&nbsp;be&nbsp;signs&nbsp;of&nbsp;a&nbsp;severe&nbsp;allergic&nbsp;reaction&nbsp;(hypersensitivity).&nbsp;</p></li></ul><ul><li><p>experience&nbsp;puffiness&nbsp;in&nbsp;your&nbsp;face&nbsp;or&nbsp;ankles,&nbsp;blood&nbsp;in&nbsp;your&nbsp;urine&nbsp;or&nbsp;brown-coloured&nbsp;urine&nbsp;or&nbsp;you notice&nbsp;you&nbsp;urinate&nbsp;less&nbsp;than&nbsp;usual&nbsp;(glomerulonephritis).&nbsp;</p></li></ul><p>&nbsp;</p><p>Inflammation&nbsp;of&nbsp;the&nbsp;aorta&nbsp;(the&nbsp;large&nbsp;blood&nbsp;vessel&nbsp;which&nbsp;transports&nbsp;blood&nbsp;from&nbsp;the&nbsp;heart&nbsp;to&nbsp;the&nbsp;body) has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience&nbsp;thesesymptoms.&nbsp;</p><p>&nbsp;</p><p><strong>Loss of response to filgrastim&nbsp;</strong></p><p>&nbsp;</p><p>If&nbsp;you&nbsp;experience&nbsp;a&nbsp;loss&nbsp;of&nbsp;response&nbsp;or&nbsp;failure&nbsp;to&nbsp;maintain&nbsp;a&nbsp;response&nbsp;with&nbsp;filgrastim&nbsp;treatment,&nbsp;your doctor will investigate the reasons why including whether you have developed antibodies which&nbsp;neutralise&nbsp;filgrastim&rsquo;s&nbsp;activity.&nbsp;</p><p>&nbsp;</p><p>Your doctor may want to monitor you closely, see section 4 of the package leaflet.&nbsp;</p><p>&nbsp;</p><p>If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood&nbsp;(leukaemia,&nbsp;myelodysplastic&nbsp;syndrome&nbsp;[MDS]).&nbsp;You&nbsp;should&nbsp;talk&nbsp;to&nbsp;your&nbsp;doctor&nbsp;about&nbsp;your&nbsp;risks of developing cancers of the blood and what testing should be done. If you develop or are likely to develop&nbsp;cancers&nbsp;of&nbsp;the&nbsp;blood,&nbsp;you&nbsp;should&nbsp;not&nbsp;use&nbsp;Zarzio&nbsp;unless&nbsp;instructed&nbsp;by&nbsp;your&nbsp;doctor.&nbsp;</p><p>&nbsp;</p><p>If you are a stem cell donor, you must be aged between 16 and 60 years.&nbsp;</p><p>&nbsp;</p><p><strong>Take special care with other products that stimulate white blood cells.&nbsp;</strong></p><p>Zarzio&nbsp;is&nbsp;one&nbsp;of&nbsp;a&nbsp;group&nbsp;of&nbsp;products&nbsp;that&nbsp;stimulate&nbsp;the&nbsp;production&nbsp;of&nbsp;white&nbsp;blood&nbsp;cells.&nbsp;Your&nbsp;healthcare professional&nbsp;should&nbsp;always&nbsp;record&nbsp;the&nbsp;exact&nbsp;product&nbsp;you&nbsp;are&nbsp;using.&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and&nbsp;Zarzio&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding&nbsp;</strong></p><p>Zarzio&nbsp;has not been tested in pregnant or breast-feeding women.&nbsp;Zarzio&nbsp;is not recommended during pregnancy.&nbsp;</p><p>&nbsp;</p><p>It is important to tell your doctor if you:&nbsp;</p><ul><li><p>are pregnant&nbsp;orbreast-feeding;&nbsp;</p></li></ul><ul><li><p>think&nbsp;you&nbsp;may&nbsp;be&nbsp;pregnant;&nbsp;or&nbsp;</p></li><li><p>are planning to have&nbsp;ababy.&nbsp;</p></li></ul><p>If you become pregnant during&nbsp;Zarzio&nbsp;treatment, please inform your doctor.&nbsp;</p><p>Unless your doctor directs you otherwise, you must stop breast feeding if you use&nbsp;Zarzio.&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines&nbsp;</strong></p><p>Zarzio&nbsp;may have a minor influence on your ability to drive and use machines. This medicine may cause dizziness. It is advisable to wait and see how you feel after taking&nbsp;Zarzio&nbsp;and before driving or operating machinery.&nbsp;</p><p>&nbsp;</p><p><strong>Zarzio&nbsp;contains sorbitol&nbsp;</strong></p><p>&nbsp;</p><p>Zarzio&nbsp;contains sorbitol (E420).&nbsp;</p><p>&nbsp;</p><p>Sorbitol&nbsp;is&nbsp;a&nbsp;source&nbsp;of&nbsp;fructose.&nbsp;If&nbsp;you&nbsp;(or&nbsp;your&nbsp;child)&nbsp;have&nbsp;hereditary&nbsp;fructose&nbsp;intolerance&nbsp;(HFI),&nbsp;a&nbsp;rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down&nbsp;fructose,&nbsp;which&nbsp;may&nbsp;cause&nbsp;serious&nbsp;side&nbsp;effects.&nbsp;</p><p>&nbsp;</p><p>You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or&nbsp;diarrhoea.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always&nbsp;use&nbsp;this&nbsp;medicine&nbsp;exactly&nbsp;as&nbsp;your&nbsp;doctor&nbsp;has&nbsp;told&nbsp;you.&nbsp;Check&nbsp;with&nbsp;your&nbsp;doctor&nbsp;or&nbsp;pharmacist&nbsp;if you are not&nbsp;sure.&nbsp;</p><p>&nbsp;</p><p><strong>How is&nbsp;Zarzio&nbsp;given and how much should I take?&nbsp;</strong></p><p>&nbsp;</p><p>Zarzio&nbsp;is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection). It can also be given as a daily slow injection&nbsp;into the vein (known as an intravenous infusion). The usual dose varies depending on your illness and weight. Your doctor will tell you how much&nbsp;Zarzio&nbsp;you should take.&nbsp;</p><p>&nbsp;</p><p>Patients having a bone marrow transplant after chemotherapy:&nbsp;</p><p>You&nbsp;will&nbsp;normally&nbsp;receive&nbsp;your&nbsp;first&nbsp;dose&nbsp;of&nbsp;Zarzio&nbsp;at&nbsp;least&nbsp;24&nbsp;hours&nbsp;after&nbsp;your&nbsp;chemotherapy&nbsp;and&nbsp;at least&nbsp;24&nbsp;hours&nbsp;after&nbsp;receiving&nbsp;your&nbsp;bone&nbsp;marrow&nbsp;transplant.&nbsp;</p><p>&nbsp;</p><p>You, or people caring for you, can be taught how to give subcutaneous injections so that you can continue&nbsp;your&nbsp;treatment&nbsp;at&nbsp;home.&nbsp;However,&nbsp;you&nbsp;should&nbsp;not&nbsp;attempt&nbsp;this&nbsp;unless&nbsp;you&nbsp;have&nbsp;been&nbsp;properly trained&nbsp;first&nbsp;by&nbsp;your&nbsp;health&nbsp;care&nbsp;provider.&nbsp;</p><p>&nbsp;</p><p><strong>How long will I have to take&nbsp;Zarzio?&nbsp;</strong></p><p>&nbsp;</p><p>You will need to take&nbsp;Zarzio&nbsp;until your white blood cell count is normal. Regular blood tests will be taken&nbsp;to&nbsp;monitor&nbsp;the&nbsp;number&nbsp;of&nbsp;white&nbsp;blood&nbsp;cells&nbsp;in&nbsp;your&nbsp;body.&nbsp;Your&nbsp;doctor&nbsp;will&nbsp;tell&nbsp;you&nbsp;how&nbsp;long&nbsp;you will need to take&nbsp;Zarzio.&nbsp;</p><p>&nbsp;</p><p>Use in children&nbsp;</p><p>&nbsp;</p><p>Zarzio&nbsp;is&nbsp;used&nbsp;to&nbsp;treat&nbsp;children&nbsp;who&nbsp;are&nbsp;receiving&nbsp;chemotherapy&nbsp;or&nbsp;who&nbsp;suffer&nbsp;from&nbsp;severe&nbsp;low&nbsp;white blood cell count (neutropenia). The dosing in children receiving chemotherapy is the same as for adults.&nbsp;</p><p>&nbsp;</p><p><strong>If you use more&nbsp;Zarzio&nbsp;than you should&nbsp;</strong></p><p>&nbsp;</p><p>Do&nbsp;not&nbsp;increase&nbsp;the&nbsp;dose&nbsp;your&nbsp;doctor&nbsp;has&nbsp;given&nbsp;you.&nbsp;If&nbsp;you&nbsp;think&nbsp;you&nbsp;have&nbsp;injected&nbsp;more&nbsp;than&nbsp;you should,&nbsp;contact&nbsp;your&nbsp;doctor&nbsp;as&nbsp;soon&nbsp;as&nbsp;possible.&nbsp;</p><p><strong>If you forget to use&nbsp;Zarzio&nbsp;</strong></p><p>If&nbsp;you&nbsp;have&nbsp;missed&nbsp;an&nbsp;injection,&nbsp;or&nbsp;injected&nbsp;too&nbsp;little,&nbsp;contact&nbsp;your&nbsp;doctor&nbsp;as&nbsp;soon&nbsp;as&nbsp;possible.&nbsp;Do&nbsp;not take&nbsp;a&nbsp;double&nbsp;dose&nbsp;to&nbsp;make&nbsp;up&nbsp;for&nbsp;any&nbsp;missed&nbsp;doses.&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p>&nbsp;</p><p>Please tell your doctor immediately&nbsp;during treatment:&nbsp;</p><ul><li><p>if&nbsp;you&nbsp;experience&nbsp;an&nbsp;allergic&nbsp;reaction&nbsp;including&nbsp;weakness,&nbsp;drop&nbsp;in&nbsp;blood&nbsp;pressure,&nbsp;difficulty breathing, swelling of the face (anaphylaxis), skin rash, itchy rash (urticaria), swelling of the face lips,&nbsp;mouth,&nbsp;tongue&nbsp;or&nbsp;throat&nbsp;(angioedema)&nbsp;and&nbsp;shortness&nbsp;of&nbsp;breath&nbsp;(dyspnoea).&nbsp;</p></li><li><p>if&nbsp;you&nbsp;experience&nbsp;a&nbsp;cough,&nbsp;fever&nbsp;and&nbsp;difficulty&nbsp;breathing&nbsp;(dyspnoea)&nbsp;as&nbsp;this&nbsp;can&nbsp;be&nbsp;a&nbsp;sign&nbsp;of&nbsp;Acute&nbsp;Respiratory&nbsp;Distress&nbsp;Syndrome&nbsp;(ARDS).&nbsp;</p></li><li><p>if&nbsp;you&nbsp;get&nbsp;left&nbsp;upper&nbsp;belly&nbsp;(abdominal)&nbsp;pain,&nbsp;pain&nbsp;below&nbsp;the&nbsp;left&nbsp;rib&nbsp;cage&nbsp;or&nbsp;pain&nbsp;at&nbsp;the&nbsp;tip&nbsp;of your shoulder, as there may be a problem with your spleen [enlargement of the spleen (splenomegaly)&nbsp;or&nbsp;rupture&nbsp;of&nbsp;the&nbsp;spleen].&nbsp;</p></li><li><p>if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria).&nbsp;Your&nbsp;doctor&nbsp;may&nbsp;regularly&nbsp;test&nbsp;your&nbsp;urine&nbsp;if&nbsp;you&nbsp;experience&nbsp;this&nbsp;side&nbsp;effect&nbsp;or&nbsp;if protein&nbsp;is&nbsp;found&nbsp;in&nbsp;your&nbsp;urine&nbsp;(proteinuria).&nbsp;</p></li></ul><ul><li><p>if&nbsp;you&nbsp;have&nbsp;any&nbsp;of&nbsp;the&nbsp;following&nbsp;or&nbsp;combination&nbsp;of&nbsp;the&nbsp;following&nbsp;side&nbsp;effects:&nbsp;</p></li></ul><p>- swelling&nbsp;or&nbsp;puffiness,&nbsp;which&nbsp;may&nbsp;be&nbsp;associated&nbsp;with&nbsp;passing&nbsp;water&nbsp;less&nbsp;frequently,&nbsp;difficulty&nbsp;breathing,&nbsp;abdominal&nbsp;swelling&nbsp;and&nbsp;feeling&nbsp;of&nbsp;fullness,&nbsp;and&nbsp;a&nbsp;general&nbsp;feeling&nbsp;of tiredness.&nbsp;These&nbsp;symptoms&nbsp;generally&nbsp;develop&nbsp;in&nbsp;a&nbsp;rapid&nbsp;fashion.&nbsp;</p><p>These&nbsp;could&nbsp;be&nbsp;symptoms&nbsp;of&nbsp;a&nbsp;condition&nbsp;called&nbsp;&ldquo;Capillary&nbsp;Leak&nbsp;Syndrome&rdquo;&nbsp;which&nbsp;causes&nbsp;blood to&nbsp;leak&nbsp;from&nbsp;the&nbsp;small&nbsp;blood&nbsp;vessels&nbsp;into&nbsp;your&nbsp;body&nbsp;and&nbsp;needs&nbsp;urgent&nbsp;medical&nbsp;attention.&nbsp;</p><ul><li><p>if&nbsp;you&nbsp;have&nbsp;a&nbsp;combination&nbsp;of&nbsp;any&nbsp;of&nbsp;the&nbsp;following&nbsp;symptoms:&nbsp;</p></li></ul><p>- fever,&nbsp;or&nbsp;shivering,&nbsp;or&nbsp;feeling&nbsp;very&nbsp;cold,&nbsp;high&nbsp;heart&nbsp;rate,&nbsp;confusion&nbsp;or&nbsp;disorientation,&nbsp;shortness&nbsp;of&nbsp;breath,&nbsp;extreme&nbsp;pain&nbsp;or&nbsp;discomfort&nbsp;and&nbsp;clammy&nbsp;or&nbsp;sweaty&nbsp;skin.&nbsp;</p><p>These could be symptoms of a condition called &ldquo;sepsis&rdquo; (also called &quot;blood poisoning&quot;), a severe infection with whole-body inflammatory response which can be life threatening and needs urgent medical attention.&nbsp;</p><ul><li><p>if you experience kidney injury (glomerulonephritis). Kidney injury has been seen in patients who&nbsp;received&nbsp;filgrastim.&nbsp;Call&nbsp;your&nbsp;doctor&nbsp;right&nbsp;away&nbsp;if&nbsp;you&nbsp;experience&nbsp;puffiness&nbsp;in&nbsp;your&nbsp;face&nbsp;or&nbsp;ankles,&nbsp;blood&nbsp;in&nbsp;your&nbsp;urine&nbsp;or&nbsp;brown-coloured&nbsp;urine&nbsp;or&nbsp;you&nbsp;notice&nbsp;you&nbsp;urinate&nbsp;less&nbsp;than&nbsp;usual.&nbsp;</p></li></ul><p>&nbsp;</p><p>A&nbsp;common&nbsp;side&nbsp;effect&nbsp;of&nbsp;filgrastim&nbsp;use&nbsp;is&nbsp;pain&nbsp;in&nbsp;your&nbsp;muscles&nbsp;or&nbsp;bones&nbsp;(musculoskeletal&nbsp;pain),&nbsp;which can&nbsp;be&nbsp;helped&nbsp;by&nbsp;taking&nbsp;standard&nbsp;pain&nbsp;relief&nbsp;medicines&nbsp;(analgesics).&nbsp;In&nbsp;patients&nbsp;undergoing&nbsp;a&nbsp;stem&nbsp;cell or bone marrow transplant, Graft versus Host Disease (GvHD) may occur- this is a reaction of the donor&nbsp;cells&nbsp;against&nbsp;the&nbsp;patient&nbsp;receiving&nbsp;the&nbsp;transplant;&nbsp;signs&nbsp;and&nbsp;symptoms&nbsp;include&nbsp;rash&nbsp;on&nbsp;the&nbsp;palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints. Very commonly seen in normal stem cell donors is increase in white blood cells (leukocytosis) and decrease of platelets which reduces the ability of blood to clot (thrombocytopenia),&nbsp;these&nbsp;will&nbsp;be&nbsp;monitored&nbsp;by&nbsp;your&nbsp;doctor.&nbsp;</p><p>&nbsp;</p><p>Very common side effects&nbsp;(may affect more than 1 in 10 people)&nbsp;</p><ul><li><p>decrease&nbsp;of&nbsp;platelets&nbsp;which&nbsp;reduces&nbsp;the&nbsp;ability&nbsp;of&nbsp;blood&nbsp;to&nbsp;clot&nbsp;(thrombocytopenia)&nbsp;</p></li><li><p>low&nbsp;red&nbsp;blood&nbsp;cell&nbsp;count&nbsp;(anaemia)&nbsp;</p></li><li><p>headache&nbsp;</p></li><li><p>diarrhoea&nbsp;</p></li></ul><ul><li><p>vomiting&nbsp;</p></li><li><p>nausea&nbsp;</p></li></ul><ul><li><p>unusual&nbsp;hair&nbsp;loss&nbsp;or&nbsp;thinning&nbsp;(alopecia)&nbsp;</p></li><li><p>tiredness&nbsp;(fatigue)&nbsp;</p></li><li><p>soreness&nbsp;and&nbsp;swelling&nbsp;of&nbsp;the&nbsp;digestive&nbsp;tract&nbsp;lining&nbsp;which&nbsp;runs&nbsp;from&nbsp;the&nbsp;mouth&nbsp;to&nbsp;the&nbsp;anus (mucosalinflammation)&nbsp;</p></li><li><p>fever&nbsp;(pyrexia)&nbsp;</p></li></ul><p>&nbsp;</p><p>Common side effects&nbsp;(may affect up to 1 in 10 people)&nbsp;</p><ul><li><p>inflammation&nbsp;of&nbsp;the&nbsp;lung&nbsp;(bronchitis)&nbsp;</p></li><li><p>upper&nbsp;respiratory&nbsp;tract&nbsp;infection&nbsp;</p></li><li><p>urinary tract&nbsp;infection&nbsp;</p></li><li><p>decreased&nbsp;appetite&nbsp;</p></li></ul><ul><li><p>trouble&nbsp;sleeping&nbsp;(insomnia)&nbsp;</p></li><li><p>dizziness&nbsp;</p></li><li><p>decreased&nbsp;feeling&nbsp;of&nbsp;sensitivity,&nbsp;especially&nbsp;in&nbsp;the&nbsp;skin&nbsp;(hypoaesthesia)&nbsp;</p></li><li><p>tingling&nbsp;or&nbsp;numbness&nbsp;of&nbsp;the&nbsp;hands&nbsp;or&nbsp;feet&nbsp;(paraesthesia)&nbsp;</p></li><li><p>low&nbsp;blood&nbsp;pressure&nbsp;(hypotension)&nbsp;</p></li></ul><ul><li><p>high&nbsp;blood&nbsp;pressure&nbsp;(hypertension)&nbsp;</p></li><li><p>cough&nbsp;</p></li><li><p>coughing&nbsp;up&nbsp;blood&nbsp;(haemoptysis)&nbsp;</p></li><li><p>pain&nbsp;in&nbsp;your&nbsp;mouth&nbsp;and&nbsp;throat&nbsp;(oropharyngeal&nbsp;pain)&nbsp;</p></li><li><p>nose&nbsp;bleeds(epistaxis)&nbsp;</p></li></ul><ul><li><p>constipation&nbsp;</p></li><li><p>oral&nbsp;pain&nbsp;</p></li><li><p>enlargement&nbsp;of&nbsp;the&nbsp;liver&nbsp;(hepatomegaly)&nbsp;</p></li><li><p>rash&nbsp;</p></li><li><p>redness&nbsp;of&nbsp;the&nbsp;skin&nbsp;(erythema)&nbsp;</p></li></ul><ul><li><p>musclespasm&nbsp;</p></li><li><p>pain&nbsp;when&nbsp;passing&nbsp;urine&nbsp;(dysuria)&nbsp;</p></li><li><p>chest&nbsp;pain&nbsp;</p></li><li><p>pain&nbsp;</p></li><li><p>generalised&nbsp;weakness&nbsp;(asthenia)&nbsp;</p></li></ul><ul><li><p>generally&nbsp;feeling&nbsp;unwell&nbsp;(malaise)&nbsp;</p></li><li><p>swelling&nbsp;in&nbsp;the&nbsp;hands&nbsp;and&nbsp;feet&nbsp;(oedema&nbsp;peripheral)&nbsp;</p></li><li><p>increase&nbsp;of&nbsp;certain&nbsp;enzymes&nbsp;in&nbsp;the&nbsp;blood&nbsp;</p></li><li><p>changes&nbsp;in&nbsp;blood&nbsp;chemistry&nbsp;</p></li><li><p>transfusion&nbsp;reaction&nbsp;</p></li></ul><p>&nbsp;</p><p>Uncommon side effects&nbsp;(may affect up to 1 in 100 people)&nbsp;</p><ul><li><p>increase&nbsp;in&nbsp;white&nbsp;blood&nbsp;cells&nbsp;(leukocytosis)&nbsp;</p></li><li><p>allergic&nbsp;reaction&nbsp;(hypersensitivity)&nbsp;</p></li><li><p>rejection&nbsp;of&nbsp;transplanted&nbsp;bone&nbsp;marrow&nbsp;(graft&nbsp;versus&nbsp;host&nbsp;disease)&nbsp;</p></li></ul><ul><li><p>high&nbsp;uric&nbsp;acid&nbsp;levels&nbsp;in&nbsp;the&nbsp;blood,&nbsp;which&nbsp;may&nbsp;cause&nbsp;gout&nbsp;(hyperuricaemia)&nbsp;(Blood&nbsp;uric&nbsp;acid increased)&nbsp;</p></li><li><p>liver&nbsp;damage&nbsp;caused&nbsp;by&nbsp;blocking&nbsp;of&nbsp;the&nbsp;small&nbsp;veins&nbsp;within&nbsp;the&nbsp;liver&nbsp;(veno-occlusive&nbsp;disease)&nbsp;</p></li><li><p>lungs&nbsp;do&nbsp;not&nbsp;function&nbsp;as&nbsp;they&nbsp;should,&nbsp;causing&nbsp;breathlessness&nbsp;(respiratory&nbsp;failure)&nbsp;</p></li><li><p>swelling&nbsp;and/or&nbsp;fluid&nbsp;in&nbsp;the&nbsp;lungs&nbsp;(pulmonary&nbsp;oedema)&nbsp;</p></li><li><p>inflammation&nbsp;of&nbsp;the&nbsp;lungs&nbsp;(interstitial&nbsp;lung&nbsp;disease)&nbsp;</p></li></ul><ul><li><p>abnormal&nbsp;x-rays&nbsp;of&nbsp;the&nbsp;lungs&nbsp;(lung&nbsp;infiltration)&nbsp;</p></li><li><p>bleeding&nbsp;from&nbsp;the&nbsp;lung&nbsp;(pulmonary&nbsp;haemorrhage)&nbsp;</p></li><li><p>lack&nbsp;of&nbsp;absorption&nbsp;of&nbsp;oxygen&nbsp;in&nbsp;the&nbsp;lung&nbsp;(hypoxia)&nbsp;</p></li><li><p>bumpy&nbsp;skin&nbsp;rash&nbsp;(rash&nbsp;macuo-papular)&nbsp;</p></li><li><p>disease&nbsp;which&nbsp;causes&nbsp;bones&nbsp;to&nbsp;become&nbsp;less&nbsp;dense,&nbsp;making&nbsp;them&nbsp;weaker,&nbsp;more&nbsp;brittle&nbsp;and&nbsp;likely to&nbsp;break(osteoporosis)&nbsp;</p></li></ul><ul><li><p>injection site&nbsp;reaction&nbsp;</p></li></ul><p>Rare side effects&nbsp;(may affect up to 1 in 1,000 people):&nbsp;</p><ul><li><p>severe&nbsp;pain&nbsp;in&nbsp;the&nbsp;bones,&nbsp;chest,&nbsp;gut&nbsp;or&nbsp;joints&nbsp;(sickle&nbsp;cell&nbsp;anaemia&nbsp;with&nbsp;crisis)&nbsp;</p></li><li><p>sudden&nbsp;life-threatening&nbsp;allergic&nbsp;reaction&nbsp;(anaphylactic&nbsp;reaction)&nbsp;</p></li><li><p>pain&nbsp;and&nbsp;swelling&nbsp;of&nbsp;the&nbsp;joints,&nbsp;similar&nbsp;to&nbsp;gout&nbsp;(pseudogout)&nbsp;</p></li><li><p>a&nbsp;change&nbsp;in&nbsp;how&nbsp;your&nbsp;body&nbsp;regulates&nbsp;fluids&nbsp;within&nbsp;your&nbsp;body&nbsp;and&nbsp;may&nbsp;result&nbsp;in&nbsp;puffiness&nbsp;(fluid&nbsp;volumedisturbances)&nbsp;</p></li></ul><ul><li><p>inflammation&nbsp;of&nbsp;the&nbsp;blood&nbsp;vessels&nbsp;in&nbsp;the&nbsp;skin&nbsp;(cutaneous&nbsp;vasculitis)&nbsp;</p></li><li><p>plum-coloured,&nbsp;raised,&nbsp;painful&nbsp;sores&nbsp;on&nbsp;the&nbsp;limbs&nbsp;and&nbsp;sometimes&nbsp;the&nbsp;face&nbsp;and&nbsp;neck&nbsp;with&nbsp;a&nbsp;fever (Sweetssyndrome)&nbsp;</p></li><li><p>worsening of&nbsp;rheumatoidarthritis&nbsp;</p></li><li><p>unusual&nbsp;change&nbsp;in&nbsp;the&nbsp;urine&nbsp;</p></li><li><p>bone&nbsp;densitydecreased&nbsp;</p></li></ul><ul><li><p>inflammation&nbsp;of&nbsp;the&nbsp;aorta&nbsp;(the&nbsp;large&nbsp;blood&nbsp;vessel&nbsp;which&nbsp;transports&nbsp;blood&nbsp;from&nbsp;the&nbsp;heart&nbsp;to&nbsp;the body), see section&nbsp;2.&nbsp;</p></li></ul><p>&nbsp;</p><p>Reporting of side effects&nbsp;</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.&nbsp;</p><p>By reporting&nbsp;side affects&nbsp;you can help provide more information on the safety of this medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.&nbsp;</p><p>&nbsp;</p><p>Do&nbsp;not&nbsp;use&nbsp;this&nbsp;medicine&nbsp;after&nbsp;the&nbsp;expiry&nbsp;date&nbsp;which&nbsp;is&nbsp;stated&nbsp;on&nbsp;the&nbsp;carton&nbsp;and&nbsp;on&nbsp;the&nbsp;syringe&nbsp;label after&nbsp;EXP.&nbsp;The&nbsp;expiry&nbsp;date&nbsp;refers&nbsp;to&nbsp;the&nbsp;last&nbsp;day&nbsp;of&nbsp;that&nbsp;month.&nbsp;</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C).&nbsp;</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light. Accidental freezing will not harm&nbsp;Zarzio.&nbsp;</p><p>&nbsp;</p><p>The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum&nbsp;72&nbsp;hours&nbsp;(but&nbsp;not&nbsp;above&nbsp;25&deg;C).&nbsp;At&nbsp;the&nbsp;end&nbsp;of&nbsp;this&nbsp;period,&nbsp;the&nbsp;product&nbsp;should&nbsp;not&nbsp;be&nbsp;put&nbsp;back in&nbsp;the&nbsp;refrigerator&nbsp;and&nbsp;should&nbsp;be&nbsp;disposed&nbsp;of.&nbsp;</p><p>&nbsp;</p><p>Do&nbsp;not&nbsp;use&nbsp;this&nbsp;medicine&nbsp;if&nbsp;you&nbsp;notice&nbsp;discolouration,&nbsp;cloudiness&nbsp;or&nbsp;particles,&nbsp;it&nbsp;should&nbsp;be&nbsp;a&nbsp;clear,&nbsp;colourless&nbsp;to&nbsp;slightly&nbsp;yellowish&nbsp;liquid.&nbsp;</p><p>Do&nbsp;not&nbsp;throw&nbsp;away&nbsp;any&nbsp;medicines&nbsp;via&nbsp;wastewater&nbsp;or&nbsp;household&nbsp;waste.&nbsp;Ask&nbsp;your&nbsp;pharmacist&nbsp;how&nbsp;to throw&nbsp;away&nbsp;medicines&nbsp;you&nbsp;no&nbsp;longer&nbsp;use.&nbsp;These&nbsp;measures&nbsp;will&nbsp;help&nbsp;protect&nbsp;the&nbsp;environment.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What&nbsp;Zarzio&nbsp;contains&nbsp;</p><ul><li><p>The&nbsp;active&nbsp;substance&nbsp;is&nbsp;filgrastim.&nbsp;</p></li></ul><p>Zarzio&nbsp;30&nbsp;MU/0.5&nbsp;ml&nbsp;solution&nbsp;for&nbsp;injection&nbsp;or&nbsp;infusion&nbsp;in&nbsp;pre-filled&nbsp;syringe:&nbsp;Each&nbsp;pre-filled syringe&nbsp;contains&nbsp;30&nbsp;MU&nbsp;filgrastim&nbsp;in&nbsp;0.5&nbsp;ml,&nbsp;corresponding&nbsp;to&nbsp;60&nbsp;MU/ml.&nbsp;</p><p>Zarzio&nbsp;48&nbsp;MU/0.5&nbsp;ml&nbsp;solution&nbsp;for&nbsp;injection&nbsp;or&nbsp;infusion&nbsp;in&nbsp;pre-filled&nbsp;syringe:&nbsp;Each&nbsp;pre-filled syringe&nbsp;contains&nbsp;48&nbsp;MU&nbsp;filgrastim&nbsp;in&nbsp;0.5&nbsp;ml,&nbsp;corresponding&nbsp;to&nbsp;96&nbsp;MU/ml&nbsp;</p><ul><li><p>The&nbsp;other&nbsp;ingredients&nbsp;are&nbsp;glutamic&nbsp;acid,&nbsp;sorbitol&nbsp;(E420),&nbsp;polysorbate&nbsp;80&nbsp;and&nbsp;water&nbsp;for injections.&nbsp;</p></li></ul><ul><li><p>The&nbsp;needle&nbsp;cap&nbsp;of&nbsp;the&nbsp;syringe&nbsp;may&nbsp;contain&nbsp;dry&nbsp;rubber&nbsp;(latex).&nbsp;</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zarzio is a clear, colourless to slightly yellowish solution for injection or infusion in pre-filled syringe. 
 
Zarzio is available in packs containing 1, 3, 5 or 10 pre-filled syringes with injection needle and with or without a needle safety guard. 
 
Not all pack sizes may be marketed. 
 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing&nbsp;Authorisation&nbsp;Holder&nbsp;</strong></p><p>Sandoz GmbH Biochemiestr.10 6250 Kundl Austria&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer&nbsp;</strong></p><p>Sandoz GmbH&nbsp;Biochemiestr. 10&nbsp;</p><p>6336&nbsp;Langkampfen&nbsp;Austria&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>عقار&nbsp;زارزيو&nbsp;هو أحد عوامل نمو خلايا الدَّم البيضاء (عامل تحفيز مستعمرات الخلايا المحببة) وينتمي&nbsp;إلى مجموعة من البروتينات&nbsp;تُسمى السِّيتوكينات. عوامل النمو هي البروتينات التي&nbsp;تُنتَج&nbsp;بشكل طبيعي في الجسم ولكن يُمكِن صناعتها أيضًا بالاستعانة بالتقنية الحيوية لاستخدامها كدواء. يعمل عقار&nbsp;زارزيو&nbsp;عن&nbsp;طريق&nbsp;حث النخاع العظمي على&nbsp;إنتاج&nbsp;المزيد من خلايا الدَّم البيضاء.&nbsp;</p><p>يُمكِن أن يحدث انخفاض في عدد خلايا الدَّم البيضاء (قلة خلايا العَدِلات) لأسباب&nbsp;كثيرة&nbsp;وينتج&nbsp;منه&nbsp;انخفاض&nbsp;قدرة جسمك على مكافحة العدوى. يحفز عقار&nbsp;زارزيو&nbsp;النخاع العظمي لإنتاج خلايا بيضاء جديدة&nbsp;سريعًا.&nbsp;</p><p>يُمكِن&nbsp;استخدام عقار&nbsp;زارزيو&nbsp;للأسباب التَّالية:&nbsp;</p><ul><li><p>لزيادة عدد خلايا الدَّم البيضاء بعد العلاج الكيميائي؛ للمساعدة&nbsp;في&nbsp;الوقاية من العدوى.&nbsp;</p></li></ul><ul><li><p>لزيادة عدد خلايا الدَّم البيضاء بعد عملية زرع النخاع العظمي؛ للمساعدة&nbsp;في&nbsp;الوقاية من العدوى.&nbsp;</p></li><li><p>قبل تلقي جرعات مرتفعة من العلاج الكيميائي لجعل النخاع العظمي ينتج المزيد من الخلايا الجذعية التي يُمكِن جمعها وإعادتها إليك بعد علاجك. يُمكِن أخذ هذه الخلايا الجذعية منك أو من أحد المتبرعين. ستعود الخلايا الجذعية بعد ذلك إلى النخاع العظمي وتنتج خلايا الدَّم.&nbsp;</p></li><li><p>لزيادة عدد خلايا الدَّم&nbsp;البيضاء&nbsp;إذا كنت&nbsp;تُعاني حالة مُزمِنة وشديدة من قلة خلايا العَدِلات؛ للمساعدة&nbsp;في&nbsp;الوقاية من العدوى.&nbsp;</p></li><li><p>لدى&nbsp;المرضى المُصابين بحالة متقدمة من&nbsp;عدوى&nbsp;فيروس&nbsp;نقص المناعة&nbsp;البشري سيُساعد العقار في تقليل خطر الإصابة بعدوى.&nbsp;</p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا&nbsp;</strong><strong>تستخدم&nbsp;عقار&nbsp;زارزيو&nbsp;في الحالات التَّالية:&nbsp;</strong></p><ul><li><p>إذا كنت تعاني حساسية&nbsp;تجاه&nbsp;فيلجراستيم&nbsp;أو&nbsp;أيٍّ&nbsp;من المكونات الأخرى بهذا الدَّواء (المدرجة بالقسم: 6).&nbsp;</p></li></ul><p><strong>تحذيرات واحتياطات&nbsp;</strong></p><p>تحدَّث إلى طبيبك أو الصيدلي الخاص بك أو الممرض(ة) قبل استخدام عقار&nbsp;زارزيو.&nbsp;</p><p>توخ حذرًا خاصًّا مع العلاج بعقار&nbsp;زارزيو&nbsp;إذا كنت قد تعرَّضت من قبل لأحد تفاعلات الحساسية&nbsp;تجاه مادة&nbsp;اللاتكس.&nbsp;</p><p>يُرجى إخبار طبيبك قبل بدء العلاج&nbsp;إذا كنت مصابًا بما يلي:&nbsp;</p><ul><li><p>هشاشة&nbsp;العظام (مرض&nbsp;يصيب العظام)؛&nbsp;</p></li><li><p>أنيميا الخلايا المنجلية؛ إذ قد يُؤدي عقار&nbsp;زارزيو&nbsp;إلى حدوث أزمة الخلايا المنجلية.&nbsp;</p></li></ul><p>أثناء العلاج بعقار&nbsp;زارزيو، يُرجى إخبار طبيبك فورًا إذا حدث أيٌّ&nbsp;مما يلي:&nbsp;</p><ul><li><p>أُصِبت بألم في الجزء العلوي الأيسر من البطن أو بألم أسفل الجهة اليسرى من القفص&nbsp;الصَّدري&nbsp;أو على طرف&nbsp;كتفك الأيسر [قد تكون هذه&nbsp;أعراض تضخُّم الطحال، أو ربما حدوث تمزُّق في الطحال].&nbsp;</p></li><li><p>لاحظت حدوث نزيف أو تكدُّم غير مُعتاد [قد تكون هذه أعراض انخفاض عدد الصفائح الدَّموية (نقحن الصفائح&nbsp;الدَّموية)، مع انخفاض قدرة الدَّم لديك على التجلُّط].&nbsp;</p></li><li><p>ظهرت لديك علامات حساسية مفاجئة مثل: الطفح الجلدي&nbsp;أو الحكة أو الشرى على الجلد، تورُّم الوجه أو الشفتين&nbsp;أو اللسان أو أجزاء أخرى من الجسم، ضيق بالتَّنفس، أزيز بالصدر أو مشاكل في التنفس؛ إذ قد تكون هذه علامات على الإصابة بتفاعل حساسية شديد (فرط حساسية).&nbsp;</p></li><li><p>تعرَّضت لانتفاخ بالوجه أو الكاحلين، وجود&nbsp;دم لديك في البول أو بول بني اللون أو لاحظت أنك تتبول بمعدل أقل&nbsp;من المُعتاد (التهاب&nbsp;كبيبات&nbsp;الكُلى).&nbsp;</p></li></ul><p>تم الإبلاغ عن حدوث التهاب في الشريان الأورطي (الوعاء الدَّموي الكبير الذي ينقل الدَّم من القلب الى الجسم) بصورة نادرة في مرضى السرطان والمتبرعين الأصحاء. قد تتضمن الأعراض&nbsp;حُمّى&nbsp;وألمًا بالبطن وشعورًا بالتَوَعُّك&nbsp;وألمًا بالظهر وزيادة الدلالات الالتهابية. أخبر طبيبك إذا كنت تعاني هذه الأعراض.&nbsp;</p><p><strong>فقدان الاستجابة&nbsp;للفيلجراستيم&nbsp;</strong></p><p>إذا تعرَّضت لفقدان الاستجابة أو الفشل في الحفاظ على الاستجابة مع العلاج&nbsp;بفيلجراستيم، سيبحث طبيبك أسباب ذلك ويشمل ذلك ما إذا كان جسمك قد أنتج أجسامًا مضادة&nbsp;تُبطِل&nbsp;نشاط&nbsp;فيلجراستيم&nbsp;أم لا.&nbsp;</p><p>قد يرغب طبيبك في مراقبتك عن كثب، انظر قسم: 4 في نشرة العبوة.&nbsp;</p><p>إذا كنت&nbsp;مريضًا&nbsp;مُصابًا بحالة مُزمِنة وشديدة من قلة خلايا العَدِلات، فقد تكون&nbsp;مُعرَّضًا&nbsp;لخطر الإصابة بسرطان الدَّم (اللوكيميا، متلازمة خلل التَّنسج النخاعي). يجب عليك التحدُّث إلى طبيبك بشأن مخاطر إصابتك بمرض سرطان الدَّم وما هي الاختبارات التي يجب إجراؤها. إذا&nbsp;أُصِبت أو كان من المُحتَمَل&nbsp;أن تُصاب&nbsp;بسرطانات الدَّم، فيجب أَلَّا تستخدم عقار&nbsp;زارزيو&nbsp;ما لم يوجهك طبيبك باستخدامه.&nbsp;</p><p>إذا كنت مُتبرعًا بخلايا جذعية، فيجب أن يتراوح عُمْرك بين 16 و60 عامًا.&nbsp;</p><p><strong>توخ حذرًا خاصًا مع&nbsp;المُنتَجات&nbsp;الأخرى التي تحفز خلايا الدَّم البيضاء.&nbsp;</strong></p><p>عقار&nbsp;زارزيو&nbsp;هو واحد من مجموعة من&nbsp;المُنتَجات&nbsp;التي تحفز إنتاج خلايا الدَّم&nbsp;البيضاء. يجب دائمًا على&nbsp;اختصاصي&nbsp;الرعاية&nbsp;الصحية&nbsp;المتابع لك تسجيل المُنتَج&nbsp;الصحيح&nbsp;الذي تستخدمه.&nbsp;</p><p><strong>تناول</strong><strong>&nbsp;أدوية أخرى مع عقار&nbsp;زارزيو&nbsp;</strong></p><p><img alt="Text Box" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAcAAAAPCAYAAAAoAdW+AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAABZSURBVChTY6AYFAPxfyB+A8SGIAEYAHFSIEwGHyBeCGFCgAQQ80CYYAmQAhQAEgAZexeIJUEC2ADI7j0QJiYAGT8LwsQEIMf1QpgQAPMGCIOMhDlusAEGBgCPBQ0wsxJiSQAAAABJRU5ErkJgggAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==" />يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول&nbsp;أو تناولت&nbsp;مؤخرًا&nbsp;أو قد تتناول&nbsp;أيَّ&nbsp;أدوية&nbsp;أخرى.&nbsp;</p><p>&nbsp;</p><p>ا<strong>لحمل والرضاعة الطبيعية&nbsp;</strong></p><p>لم يتم اختبار عقار&nbsp;زارزيو&nbsp;لدى&nbsp;السيدات الحوامل أو المُرضِعات.&nbsp;</p><p>لا يُنصح بتناول&nbsp;زارزيو&nbsp;أثناء الحمل.&nbsp;</p><p>&nbsp;</p><p>من المهم أن تخبري طبيبكِ&nbsp;في الحالات الآتية:&nbsp;</p><ul><li><p>إذا كنتِ&nbsp;حاملاً&nbsp;أو&nbsp;مرضعًا؛&nbsp;</p></li><li><p>إذا كنتِ&nbsp;تعتقدين&nbsp;بآنكِ&nbsp;قد تكونين حاملاً، أو&nbsp;</p></li><li><p>إذا كنتِ&nbsp;تخططين للحَمْل.&nbsp;</p></li></ul><p>إذا أصبحتِ&nbsp;حاملاً&nbsp;أثناء العلاج بعقار&nbsp;زارزيو، فيُرجى إبلاغ طبيبكِ.&nbsp;</p><p>يجب عليكِ&nbsp;التَّوقف عن ممارسة الرضاعة الطبيعية إذا كنتِ&nbsp;تستخدمين عقار&nbsp;زارزيو، ما لم يوجهكِ&nbsp;طبيبكِ&nbsp;بخلاف ذلك.&nbsp;</p><p><strong>القيادة واستخدام الآلات&nbsp;</strong></p><p>قد يكون لعقار&nbsp;زارزيو&nbsp;تأثير طفيف على قدرتك على قيادة المركبات واستخدام الآلات. قد يُسبب هذا الدَّواء دوخة. من المستحسن الانتظار ورؤية ما تشعر به بعد تلقي عقار&nbsp;زارزيو&nbsp;وقبل قيادة المركبات أو تشغيل الآلات.&nbsp;</p><p><strong>عقار&nbsp;زارزيو&nbsp;يحتوي على&nbsp;السوربيتول</strong>&nbsp;</p><p>يحتوي عقار&nbsp;زارزيو&nbsp;على&nbsp;السوربيتول&nbsp;(E420).&nbsp;</p><p>السوربيتول&nbsp;هو أحد مصادر الفركتوز. إذا كان لديك (أو لدى طفلك) حالة وراثية من عدم تحمُّل الفركتوز، وهو اضطراب وراثي نادر، فيجب عليك (أو على طفلك) عدم تلقي هذا الدَّواء. المرضى ممن لديهم حالة وراثية&nbsp;من عدم تحمُّل&nbsp;الفركتوز لا تستطيع أجسامهم تكسير الفركتوز، مما قد يسبب آثارًا جانبية خطيرة.&nbsp;</p><p>يجب عليك إخبار طبيبك قبل تلقي هذا الدَّواء إذا كان لديك (أو&nbsp;لدى طفلك) حالة وراثية من عدم تحمُّل&nbsp;الفركتوز أو إذا لم يعد طفلك يستطيع تناوُل الأطعمة أو المشروبات المُحلاة بسبب شعوره بالإعياء أو&nbsp;رغبته في القيء أو تعرُّضه لآثار مزعجة مثل الانتفاخ أو تقلصات المعدة أو الإسهال.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.&nbsp;</p><p>كيف يُعطى عقار&nbsp;زارزيو؟ وما الكمية التي عليَّ&nbsp;تلقيها؟&nbsp;</p><p>يعطى عقار&nbsp;زارزيو&nbsp;عادةً&nbsp;في هيئة&nbsp;حَقْن يومي في النسيج أسفل الجلد مباشرةً&nbsp;(يُعرف ذلك بالحَقْن أسفل الجلد). يُمكِن أيضًا إعطاؤه في هيئة&nbsp;حَقْن يومي بطيء في الوريد (يُعرَف ذلك&nbsp;بالتَّسريب&nbsp;الوريدي). تتباين الجرعة المُعتادة وفقًا لوزنك والمرض الذي تعانيه. سيخبرك طبيبك بالكمية التي يجب عليك تلقيها من عقار&nbsp;زارزيو.&nbsp;</p><p>المرضى ممن خضعوا لزراعة نخاع عظمي بعد تلقي العلاج الكيميائي:&nbsp;</p><p>ستتلقى&nbsp;عادةً&nbsp;جرعتك الأولى من عقار&nbsp;زارزيو&nbsp;بعد 24 ساعة على الأقل من تلقيك العلاج الكيميائي وبعد 24 ساعة على الأقل من خضوعك لزراعة النخاع العظمي.&nbsp;</p><p>يُمكِن تعليمك، أنت أو&nbsp;الأشخاص الذين يتولون رعايتك، كيفية إعطاء الحَقْن أسفل الجلد بحيث يُمكِنك مواصلة علاجك في المنزل.&nbsp;&nbsp;<br />ومع ذلك، يجب أَلَّا تحاول القيام بذلك إذا لم تتلق تدريبًا ملائمًا أولاً&nbsp;من قبل مقدم الرعاية الصحية الخاص بك.&nbsp;</p><p><strong>إلى متى&nbsp;يجب علي تلقى عقار&nbsp;زارزيو؟&nbsp;</strong></p><p>ستحتاج إلى&nbsp;تلقي عقار&nbsp;زارزيو&nbsp;حتى يصبح عدد خلايا الدَّم البيضاء لديك طبيعيًّا. سيتم إجراء اختبارات دم بصفة منتظمة؛ لمراقبة عدد خلايا الدَّم البيضاء في جسمك. سيخبرك طبيبك بالمدة التي ستحتاجها لتلقي عقار&nbsp;زارزيو.&nbsp;</p><p>الاستخدام&nbsp;لدى&nbsp;الأطفال&nbsp;</p><p>يُستَخدَم عقار&nbsp;زارزيو&nbsp;لعلاج الأطفال ممن يتلقون العلاج الكيميائي أو ممن يُعانون انخفاضًا&nbsp;شديدًا&nbsp;في عدد خلايا الدَّم البيضاء (قلة خلايا العَدِلات). الجرعات بالنسبة للأطفال الذين يتلقون العلاج الكيميائي هي نفسها بالنسبة للبالغين.&nbsp;</p><p><strong>إذا استخدمت كمية أكثر مما يجب من عقار&nbsp;زارزيو&nbsp;</strong></p><p>لا تقم بزيادة الجرعة التي أعطاها لك طبيبك. إذا اعتقدت أنك قد حَقَنت نفسك بكمية أكثر مما يجب من العقار، فاتصل&nbsp;بطبيبك بأسرع&nbsp;ما يُمكِن.&nbsp;</p><p><strong>إذا أغفلت استخدام عقار&nbsp;زارزيو&nbsp;</strong></p><p>إذا أغفلت عملية حَقْن، أو حَقَنت كمية أقل مما يجب، فاتصل بطبيبك بأسرع ما يُمكِن. لا تتلقى&nbsp;جرعة مضاعفة لتعويض أي جرعات قد تم إغفالها.&nbsp;</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك أو الممرض(ة)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.&nbsp;</p><p>يُرجى إخبار طبيبك فورًا&nbsp;إذا حدث أي مما يلي أثناء العلاج:&nbsp;</p><ul><li><p>إذا تعرَّضت لأحد تفاعلات الحساسية ويشمل ذلك الضعف وهبوط ضغط الدَّم وصعوبة التنفس&nbsp;وتورُّم الوجه (تأقًا) والطفح الجلدي والطفح الجلدي المصحوب بحكة (أرتكاريا) وتورُّم الوجه أو الشفتين أو الفم أو اللسان أو الحَلْق (وذمة وعائية) وضيق التنفس.&nbsp;</p></li><li><p>إذا تعرَّضت لسعال وحُمّى وصعوبة في التَّنفس (ضيق التَّنفس)؛ إذ قد تكون هذه علامة على الإصابة بمتلازمة ضيق التَّنفس الحاد.&nbsp;</p></li><li><p>إذا&nbsp;أُصِبت بألم في الجزء العلوي الأيسر من البطن أو بألم أسفل الجهة اليسرى من القفص الصدري أو على طرف كتفك؛ إذ قد تكون هناك مشكلة لديك بالطحال [تضخُّم الطحال أو تمزُّق في الطحال].&nbsp;</p></li><li><p>إذا كنت تُعالَج من حالة مُزمِنة وشديدة من قلة خلايا العَدِلات وكان لديك دم في البول (بيلة دموية). قد يجري طبيبك اختبارًا للبول لديك بصفة منتظمة إذا تعرَّضت لهذا الأثر الجانبي أو إذا تم العثور على بروتين لديك في البول (بيلة بروتينية).&nbsp;</p></li><li><p>إذا كان لديك أي من التَّالي أو مزيج من الآثار الجانبية التَّالية:&nbsp;</p></li><li><p>تورُّم أو انتفاخ، قد يصاحبه تبوُّل بصورة أقل تكرارًا، صعوبة في التنفس، انتفاخ البطن وشعور&nbsp;بالامتلاء، وشعور عام بالتعب. تظهر هذه الأعراض بشكل عام بشكل سريع.&nbsp;</p></li></ul><p>قد تكون هذه أعراض لحالة&nbsp;تُسمى&nbsp;&quot;متلازمة التسرُّب الشعيري&quot; وهي حالة تسبب تسرب الدَّم من الأوعية الدموية الصغيرة إلى جسمك وتحتاج إلى العناية الطبية العاجلة.&nbsp;</p><ul><li><p>إذا كنت تعاني مزيجًا&nbsp;من أي من الأعراض التَّالية:&nbsp;</p></li><li><p>حُمّى أو ارتعاش أو شعور بالبرودة الشديدة أو ارتفاع معدل ضربات القلب أو ارتباك أو&nbsp;توهان&nbsp;أو ضيق&nbsp;بالتَّنفس أو ألم شديد أو شعور غير مريح وجلد متعرّق أو مُتَنَدٍّ&nbsp;بالعرق.&nbsp;</p></li></ul><p>قد تكون هذه أعراض لحالة&nbsp;تُسمى&nbsp;&quot;تعفُّن الدَّم&quot; (تُسمى أيضًا &quot;تسمم الدَّم&quot;)، وهي عدوى شديدة مصحوبة برد فعل التهابي للجسم بالكامل والتي يمكن أن تكون مُهَدِّدة للحياة وتحتاج إلى العناية الطبية العاجلة.&nbsp;</p><ul><li><p>إذا تعرضت لإصابة في الكُلى (التهاب&nbsp;كبيبات&nbsp;الكُلى). لُوحظ وجود إصابة في الكُلى في المرضى الذين تلقوا&nbsp;فيلجراستيم. اتصل بطبيبك فورًا إذا تعرَّضت لانتفاخ بالوجه أو الكاحلين،&nbsp;أو لاحظت&nbsp;وجود دم في البول أو بول بني اللون أو لاحظت أنك تتبول بمعدل أقل من المُعتاد</p></li><li><p>أحد الآثار الجانبية الشائعة لاستخدام&nbsp;فيلجراستيم&nbsp;هو الشعور بألم لديك بالعضلات أو العظام، وهو ما يُمكِن تخفيفه عن طريق تناوُل أدوية تسكين الألم الاعتيادية (المُسَكِّنات).&nbsp;لدى&nbsp;المرضى الذين يخضعون لزراعة خلايا جذعية أو&nbsp;نخاع عظمي، فقد تحدث&nbsp;إصابة بداء&nbsp;الطُّعْمِ&nbsp;حِيَالَ&nbsp;الثَّوِيّ&nbsp;-وهو استجابة خلايا المتبرع ضد المريض متلقي الزراعة؛ تتضمن العلامات والأعراض طفحًا جلديًّا على راحتي اليدين&nbsp;أو أخمصي القدمين والتهابات وقرحًا في الفم والأمعاء والكبد والجلد أو العينين والرئتين والمهبل والمفاصل.&nbsp;لُوحظ&nbsp;بشكل شائع جدًّا&nbsp;لدى&nbsp;المتبرعين بخلايا جذعية طبيعية زيادة في عدد خلايا الدَّم البيضاء وانخفاض في عدد الصفائح الدَّموية وهو ما يقلل قدرة الدَّم على التجلط (قلة الصَّفائح الدَّموية)،&nbsp;وسيتولى طبيبك مراقبة هذه الأمور.&nbsp;</p><p><strong>الآثار الجانبية الشائعة جدًّا</strong>&nbsp;(قد تُؤثر على أكثر من 1 من بين كل 10 أشخاص)&nbsp;</p></li><li><p>انخفاض عدد الصفائح الدَّموية وهو ما يقلل قدرة الدَّم على التجلط (نقص الصَّفائح الدَّموية)&nbsp;</p></li><li><p>انخفاض عدد خلايا الدم الحمراء (فقر الدم)&nbsp;</p></li><li><p>صداع&nbsp;</p></li><li><p>إِسْهال&nbsp;</p></li><li><p>قيء&nbsp;</p></li><li><p>غثيان&nbsp;</p></li><li><p>حالة غير مُعتادة من تساقط الشعر أو ترققه (ثعلبة)&nbsp;</p></li><li><p>تعب (إرهاق)&nbsp;</p></li><li><p>قُرَح وتورُّم في بطانة الجهاز الهضمي الذي يمتد من الفم إلى فتحة الشرج (التهاب الغشاء المخاطي)&nbsp;</p></li><li><p>حُمى (ارتفاع درجة الحرارة)&nbsp;</p></li><li><p><strong>الآثار الجانبية الشَّائعة</strong>&nbsp;(قد تُؤثر&nbsp;في ما&nbsp;يصل إلى 1 من بين كل 10 أشخاص)&nbsp;</p></li><li><p>التهاب الرئة (التهاب الشُّعَب الهوائية)&nbsp;</p></li><li><p>عدوى الجهاز&nbsp;التَّنفسي العلوي&nbsp;</p></li><li><p>عدوى الجهاز البولي&nbsp;</p></li><li><p>انخفاض&nbsp;الشهية&nbsp;</p></li><li><p>صعوبات في النوم (أَرَق)&nbsp;</p></li><li><p>دوخة&nbsp;</p></li><li><p>انخفاض الإحساس، لا سيَّما في الجلد (تدنّي&nbsp;الإحساس)&nbsp;</p></li><li><p>وخز أو تنميل باليدين أو القدمين (اضطرابات الإحساس)&nbsp;</p></li><li><p>انخفاض ضغط الدَّم&nbsp;</p></li><li><p>ارتفاع ضغط الدَّم&nbsp;</p></li><li><p>سعال&nbsp;</p></li><li><p>سعال مصحوب بدم (نَفْث الدَّم [سُعال دموي])&nbsp;</p></li><li><p>ألم لديك في الفم والحَلْق (ألم بالفم والبلعوم)&nbsp;</p></li><li><p>طفح جلدي&nbsp;</p></li><li><p>احمرار الجلد (حُمامي)&nbsp;</p></li><li><p>تقلصات عضلية&nbsp;</p></li><li><p>ألم&nbsp;عند&nbsp;التبوُّل (عُسْر التَّبَوُّل)&nbsp;</p></li><li><p>ألم بالصدر&nbsp;</p></li><li><p>ألم&nbsp;</p></li><li><p>ضعف مُعَمم (وهن)&nbsp;</p></li><li><p><img alt="Text Box" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAYAAAANCAYAAACKCx+LAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAABeSURBVChTY6AI8ADxHiB+A8SGIAEQADFAAsVgHhTAVKIIggBI9Skg3g3E/4F4IRCDgQ8QgwRBCiSB+C5UDEwgGwNigyVAqkA6QDTIvpVADHcVSAXIfBAGq6YaYGAAANQaEGio4zPyAAAAAElFTkSuQmCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==" />شعور عام بالإعياء (توعُّك)&nbsp;&nbsp;</p></li><li><p>تورُّم باليدين والقدمين (وذمة طرفية)&nbsp;</p></li><li><p>زيادة بعض الإنزيمات في الدَّم&nbsp;</p></li><li><p>تغيُّرات في كيمياء الدَّم&nbsp;</p></li><li><p>تفاعلات نقل الدَّم&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p></li><li><p><strong>الآثار الجانبيَّة غير الشَّائعة&nbsp;</strong>(قد&nbsp;تُؤثر&nbsp;في ما&nbsp;يصل إلى 1 من بين كل 100 شخص)&nbsp;</p></li><li><p>زيادة عدد خلايا الدَّم البيضاء&nbsp;</p></li><li><p>تفاعلات حساسية (فرط الحساسية)&nbsp;</p></li><li><p>رفض النخاع العظمي المزروع (داء&nbsp;الطُّعْمِ&nbsp;حِيَالَ&nbsp;الثَّوِيّ)&nbsp;</p></li><li><p>ارتفاع مستويات حمض&nbsp;اليوريك&nbsp;في الدَّم، وهو ما قد يُسبب الإصابة بالنّقْرِس (فرط حمض&nbsp;اليوريك&nbsp;بالدَّم) (ارتفاع مستوى حمض&nbsp;اليوريك&nbsp;بالدَّم)&nbsp;</p></li><li><p>تلف كبدي ناجم عن انسداد الأوردة الصغيرة&nbsp;الموجوة&nbsp;في الكبد (داء الانسداد الوريدي)&nbsp;</p></li><li><p>عدم قيام الرئتين بوظائفهما على النحو الواجب، مما يُسبب عُسْر التَّنَفُّس&nbsp;(فشل الجهاز التنفسي)&nbsp;</p></li><li><p>تورم و/ أو تراكم السوائل في الرئتين (الوذمة الرئوية)&nbsp;</p></li><li><p>التهاب الرئتين (مرض الرئة الخلالي)&nbsp;</p></li><li><p>نتائج غير طبيعية لإجراء الأشعة السينية على الرئتين (ارتشاح رئوي)&nbsp;</p></li><li><p>نزيف من الرئة&nbsp;</p></li><li><p>نقص امتصاص الأكسجين في الرئة (نقص الأكسجين بالدَّم)&nbsp;</p></li><li><p>طفح جلدي غير مستو (طفح بقعي حطاطي)&nbsp;</p></li><li><p>مرض&nbsp;يُسبب&nbsp;انخفاض كثافة العظام وجعلها&nbsp;أضعف وأكثر هشاشة وعُرضة للكسر (هشاشة العظام)&nbsp;</p></li><li><p>تفاعلاً&nbsp;بموضع الحقن&nbsp;</p></li><li><p>&nbsp;</p><p><strong>الآثار الجانبية النَّادرة&nbsp;</strong>(قد&nbsp;تُؤثر&nbsp;في ما&nbsp;يصل إلى شخص واحد من بين كل 1000 شخص):&nbsp;</p></li><li><p>ألم شديد في العظام أو الصدر أو الأمعاء أو المفاصل (أنيميا الخلايا المنجلية مع التعرُّض لأزمة)&nbsp;</p></li><li><p>تفاعل حساسية مفاجئ ومُهَدِّد للحياة (تفاعل&nbsp;تَأَقِيّ)&nbsp;</p></li><li><p>ألم وتورُّم في المفاصل، مماثل للنقرس (نقرس كاذب)&nbsp;</p></li><li><p>تغيُّر في كيفية تنظيم جسمك للسوائل داخله وقد يُؤدي إلى حدوث انتفاخ (اضطرابات في كمية السوائل)&nbsp;</p></li><li><p>التهاب الأوعية الدَّموية في الجلد (التهاب الأوعية الدَّموية الجلدية)&nbsp;</p></li><li><p>قُرَح بارزة ومؤلمة أرجوانية اللون على الأطراف وفي بعض الأحيان على الوجه والرقبة مصحوبة بحُمّى&nbsp;(متلازمة&nbsp;سويتس)&nbsp;</p></li><li><p>تفاقم التهاب المفاصل&nbsp;الروماتويدي&nbsp;</p></li><li><p>تغيُّر غير مُعتاد في البول&nbsp;</p></li><li><p>انخفاض كثافة العظام&nbsp;</p></li><li><p>التهاب الشريان الأورطي (الوعاء الدَّموي الكبير الذي ينقل الدَّم من القلب إلى الجسم)، انظر قسم: 2.&nbsp;</p></li><li><p><strong>الإبلاغ عن الآثار الجانبية&nbsp;</strong></p><p>إذا كان لديك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي أو الممرضة.&nbsp;&nbsp;<br />ويشمل ذلك أي آثار جانبية محتملة غير&nbsp;تلك&nbsp;المدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة.&nbsp;</p><p><img alt="Text Box" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAYAAAANCAYAAACKCx+LAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAAAzSURBVChTYyALSALxXSD+j4R9gJjBEIhBkjBQD8TIfDAACYAkMADICLAx6ICWxlAMGBgAK+sIskJi8BAAAAAASUVORK5CYIIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==" />ابلاغك عن الآثار الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.&nbsp;</p></li><li><p>نزيف من الأنف (الرعاف)&nbsp;</p></li><li><p>إمساك&nbsp;</p></li><li><p>ألم بالفم&nbsp;</p></li><li><p>تضخُّم&nbsp;الكبد&nbsp;</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>بُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.&nbsp;</p><p>لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى ملصق السرنجة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.&nbsp;</p><p>يحفظ في الثلاجة (عند 2&mdash;8 درجة مئوية).&nbsp;</p><p>احتفظ بالسرنجة المعبأة مسبقًا داخل العبوة الكرتونية الخارجية لحمايتها من الضَّوء.&nbsp;</p><p>لن يُلحِق التَّجميد العَرَضي ضررًا بعقار&nbsp;زارزيو.&nbsp;</p><p>يُمكِن إخراج السرنجة من الثلاجة وتركها في درجة حرارة الغرفة لمدة واحدة بحد أقصى 72 ساعة (لكن ليس في درجة حرارة تتجاوز 25 درجة مئوية). في نهاية هذه الفترة، يجب عدم وضع المُنتَج مرة أخرى في الثلاجة ويجب التَّخلص منه.&nbsp;</p><p>لا تستخدم هذا الدَّواء إذا لاحظت تغيُّر لونه أو&nbsp;أصبح&nbsp;ضبابيًا&nbsp;أو&nbsp;لاحظت&nbsp;وجود جسيمات به؛ إذ يجب أن يكون الدَّواء سائلاً&nbsp;صافيًا&nbsp;وعديم اللون أو مائلاً&nbsp;إلى&nbsp;الإصفرار&nbsp;قليلاً.&nbsp;</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li><p>المادة الفعالة هي&nbsp;فيلجراستيم.&nbsp;</p></li></ul><p>عقار&nbsp;زارزيو&nbsp;30 مليون وحدة/ 0.5 مللي لتر محلول للحقن أو للتسريب في&nbsp;سرنجات&nbsp;معبأة مسبقًا: تحتوي كل سرنجة مُعبأة مُسبقًا على 30 مليون وحدة&nbsp;فيلجراستيم&nbsp;في 0.5 مللي لتر، بما يُعادِل 60 مليون وحدة/ مللي لتر.&nbsp;</p><p>عقار&nbsp;زارزيو&nbsp;48 مليون وحدة/ 0.5 مللي لتر محلول للحقن أو للتَّسريب في&nbsp;سرنجات&nbsp;معبأة مسبقًا: تحتوي كل سرنجة مُعبأة مُسبقًا على 48 مليون وحدة&nbsp;فيلجراستيم&nbsp;في 0.5 مللي لتر، بما يُعادِل 96 مليون وحدة/ مللي لتر.&nbsp;</p><ul><li><p>المكونات الأخرى هي حمض الجلوتاميك،&nbsp;سوربيتول&nbsp;(E420)،&nbsp;بوليسوربات&nbsp;80 وماء للحَقْن.&nbsp;</p></li><li><p>قد يحتوي غطاء إبرة السرنجة على المطاط الجاف (مادة&nbsp;اللاتكس).&nbsp;</p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>عقار&nbsp;زارزيو&nbsp;عبارة عن محلول صافٍ&nbsp;وعديم اللون مائل إلى&nbsp;الإصفرار&nbsp;قليلاً&nbsp;للحَقْن أو للتَّسريب في&nbsp;سرنجات&nbsp;معبأة مسبقًا.&nbsp;</p><p>يتوفر عقار&nbsp;زارزيو&nbsp;في عبوات تحتوي على 1&nbsp;أو 3 أو 5 أو 10&nbsp;سرنجات&nbsp;معبأة مسبقًا مع إبرة حَقْن ومع أو بدون آلية أمان للإبرة.&nbsp;</p><p>قد لا يتم تسويق جميع أحجام العبوات.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التَّسويق&nbsp;</strong></p><p>شركة&nbsp;ساندوز&nbsp;المحدودة&nbsp;</p><p>10&nbsp;شارع&nbsp;بايوشيمي&nbsp;(المستحضرات الحيوية)&nbsp;</p><p>6250&nbsp;كوندل&nbsp;</p><p>النمسا</p><p><strong>جهة التَّصنيع&nbsp;</strong></p><p>شركة&nbsp;ساندوز&nbsp;المحدودة&nbsp;</p><p>10&nbsp;شارع&nbsp;بيوشيمي&nbsp;شتراسه&nbsp;</p><p>6336&nbsp;لانجكامبفين&nbsp;</p><p>النمسا&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe
 Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Each ml of solution contains 60 million units (MU) (equivalent to 600 micrograms [μg]) filgrastim*. Each pre-filled syringe contains 30 MU (equivalent to 300 μg) filgrastim in 0.5 ml.

Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Each ml of solution contains 96 million units (MU) (equivalent to 960 micrograms [μg]) filgrastim*. Each pre-filled syringe contains 48 MU (equivalent to 480 μg) filgrastim in 0.5 ml.

* recombinant methionylated human granulocyte-colony stimulating factor (G-CSF) produced in
E. coli by recombinant DNA technology.

Excipient with known effect
Each ml of solution contains 50 mg sorbitol (E420). For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection or infusion in pre-filled syringe (injection or infusion). 
Clear, colourless to slightly yellowish solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.</p><p>&nbsp;</p><p>The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobilisation of peripheral blood progenitor cells (PBPCs).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of &le; 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of persistent neutropenia (ANC &le; 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim therapy should only be given in collaboration with an oncology centre which has experience in G-CSF treatment and haematology and has the necessary diagnostic facilities. The mobilisation and apheresis procedures should be performed in collaboration with an oncology- haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.</p><p>&nbsp;</p><p><u>Established cytotoxic chemotherapy</u></p><p>&nbsp;</p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p>The recommended dose of filgrastim is 0.5 MU/kg/day (5 &mu;g/kg/day). The first dose of filgrastim should be administered at least 24 hours after cytotoxic chemotherapy. In randomised clinical trials, a subcutaneous dose of 230 &mu;g/m2/day (4.0 to 8.4 &mu;g/kg/day) was used.</p><p>&nbsp;</p><p>Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Following established chemotherapy for solid tumours, lymphomas, and lymphoid leukaemia, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days. Following induction and consolidation treatment for acute myeloid leukaemia the duration of treatment may be substantially longer (up to 38 days) depending on the type, dose and schedule of cytotoxic chemotherapy used.</p><p>&nbsp;</p><p>In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 - 2 days after initiation of filgrastim therapy. However, for a sustained therapeutic response, filgrastim therapy should not be discontinued before the expected nadir has passed and the neutrophil count has recovered to the normal range. Premature discontinuation of filgrastim therapy, prior to the time of the expected neutrophil nadir, is not recommended.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Filgrastim may be given as a daily subcutaneous injection or as a daily intravenous infusion diluted in 5% glucose solution given over 30 minutes (see section 6.6). The subcutaneous route is preferred in most cases. There is some evidence from a study of single dose administration that intravenous dosing may shorten the duration of effect. The clinical relevance of this finding to multiple dose administration is not clear. The choice of route should depend on the individual clinical circumstance.</p><p>&nbsp;</p><p><u>In patients treated with myeloablative therapy followed by bone marrow transplantation</u></p><p>&nbsp;</p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p>The recommended starting dose of filgrastim is 1.0 MU/kg/day (10 &mu;g/kg/day). The first dose of filgrastim should be administered at least 24 hours following cytotoxic chemotherapy and at least 24 hours after bone marrow infusion.</p><p>&nbsp;</p><p>Once the neutrophil nadir has been passed, the daily dose of filgrastim should be titrated against the neutrophil response as follows:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Neutrophil count</strong></p></td><td style="vertical-align:top"><p><strong>Filgrastim dose adjustment</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.0 x 109/l for 3 consecutive days</p></td><td style="vertical-align:top"><p>Reduce to 0.5 MU/kg/day (5 &mu;g/kg/day)</p></td></tr><tr><td style="vertical-align:top"><p>Then, if ANC remains &gt; 1.0 x 109/l for 3 more consecutive days</p></td><td style="vertical-align:top"><p>Discontinue filgrastim</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>If the ANC decreases to &lt; 1.0 x 109/l during the treatment period, the dose of filgrastim should be re-escalated according to the above steps</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ANC = absolute neutrophil count</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Filgrastim may be given as a 30 minute or 24 hour intravenous infusion or given by continuous 24 hour subcutaneous infusion. Filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6).</p><p>&nbsp;</p><p><u>For the mobilisation of PBPCs in patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation</u></p><p>&nbsp;</p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p>The recommended dose of filgrastim for PBPC mobilisation when used alone is</p><p>1.0 MU/kg/day (10 &mu;g/kg/day) for 5 - 7 consecutive days. Timing of leukapheresis:</p><p>1 or 2 leukaphereses on days 5 and 6 are often sufficient. In other circumstances, additional leukaphereses may be necessary. Filgrastim dosing should be maintained until the last leukapheresis.</p><p>&nbsp;</p><p>The recommended dose of filgrastim for PBPC mobilisation after myelosuppressive chemotherapy is</p><p>0.5 MU/kg/day (5 &mu;g/kg/day) from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Leukapheresis should be performed during the period when the ANC rises from &lt; 0.5 x 109/l to &gt; 5.0 x 109/l. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient. In other circumstances, additional leukaphereses are recommended.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Filgrastim for PBPC mobilisation when used alone:</p><p>Filgrastim may be given as a 24 hour subcutaneous continuous infusion or subcutaneous injection. For infusions filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6).</p><p>&nbsp;</p><p>Filgrastim for PBPC mobilisation after myelosuppressive chemotherapy: Filgrastim should be given by subcutaneous injection.</p><p>&nbsp;</p><p><u>For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation</u></p><p>&nbsp;</p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p>For PBPC mobilisation in normal donors, filgrastim should be administered at</p><p>1.0 MU/kg/day (10 &mu;g/kg/day) for 4 - 5 consecutive days. Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 CD34+ cells/kg recipient bodyweight.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Filgrastim should be given by subcutaneous injection. <u>In patients with severe chronic neutropenia (SCN)</u></p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p><em>Congenital neutropenia</em></p><p>The recommended starting dose is 1.2 MU/kg/day (12 &mu;g/kg/day) as a single dose or in divided doses.</p><p>&nbsp;</p><p><em>Idiopathic or cyclic neutropenia</em></p><p>The recommended starting dose is 0.5 MU/kg/day (5 &mu;g/kg/day) as a single dose or in divided doses.</p><p>&nbsp;</p><p><em>Dose adjustment</em></p><p>Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5 x 109/l. When the response has been obtained, the</p><p>&nbsp;</p><p>minimal effective dose to maintain this level should be established. Long-term daily administration is required to maintain an adequate neutrophil count. After 1 - 2 weeks of therapy, the initial dose may be doubled or halved depending upon the patient&#39;s response. Subsequently the dose may be individually adjusted every 1 - 2 weeks to maintain the average neutrophil count between 1.5 x 109/l and 10 x 109/l. A faster schedule of dose escalation may be considered in patients presenting with severe infections. In clinical trials, 97% of patients who responded had a complete response at doses</p><p>&le; 24 &mu;g/kg/day. The long-term safety of filgrastim administration above 24 &mu;g/kg/day in patients with SCN has not been established.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Congenital, idiopathic or cyclic neutropenia: Filgrastim should be given by subcutaneous injection. <u>In patients with HIV infection</u></p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p><em>For reversal of neutropenia</em></p><p>The recommended starting dose of filgrastim is 0.1 MU/kg/day (1 &mu;g/kg/day), with titration up to a maximum of 0.4 MU/kg/day (4 &mu;g/kg/day) until a normal neutrophil count is reached and can be maintained (ANC &gt; 2.0 x 109/l). In clinical studies, &gt; 90% of patients responded at these doses, achieving reversal of neutropenia in a median of 2 days.</p><p>&nbsp;</p><p>In a small number of patients (&lt; 10%), doses up to 1.0 MU/kg/day (10 &mu;g/kg/day) were required to achieve reversal of neutropenia.</p><p>&nbsp;</p><p><em>For maintaining normal neutrophil counts</em></p><p>When reversal of neutropenia has been achieved, the minimal effective dose to maintain a normal neutrophil count should be established. Initial dose adjustment to alternate day dosing with</p><p>30 MU/day (300 &mu;g/day) is recommended. Further dose adjustment may be necessary, as determined by the patient&#39;s ANC, to maintain the neutrophil count at &gt; 2.0 x 109/l. In clinical studies, dosing with 30 MU/day (300 &mu;g/day) on 1 - 7 days per week was required to maintain the ANC &gt; 2.0 x 109/l, with the median dose frequency being 3 days per week. Long-term administration may be required to maintain the ANC &gt; 2.0 x 109/l.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Reversal of neutropenia or maintaining normal neutrophil counts: Filgrastim should be given by subcutaneous injection.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>Clinical trials with filgrastim have included a small number of elderly patients but special studies have not been performed in this group and therefore specific dosage recommendations cannot be made.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals.</p><p>Dose adjustment is not required in these circumstances. <u>Paediatric use in the SCN and cancer settings</u></p><p>Sixty-five percent of the patients studied in the SCN trial program were under 18 years of age. The efficacy of treatment was clear for this age-group, which included most patients with congenital neutropenia. There were no differences in the safety profiles for paediatric patients treated for SCN.</p><p>&nbsp;</p><p>Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy.</p><p>The dosage recommendations in paediatric patients are the same as those in adults receiving myelosuppressive cytotoxic chemotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Special warnings and precautions across indications</u></p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p><em>&nbsp;</em></p><p>Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment has been reported in patients treated with filgrastim. Permanently discontinue Zarzio in patients with clinically significant hypersensitivity. Do not administer Zarzio to patients with a history of hypersensitivity to filgrastim or pegfilgrastim.</p><p>&nbsp;</p><p><em>Pulmonary adverse effects</em></p><p><em>&nbsp;</em></p><p>Pulmonary adverse effects, in particular interstitial lung disease, have been reported after G-CSF administration. Patients with a recent history of lung infiltrates or pneumonia may be at higher risk. The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of acute respiratory distress syndrome (ARDS). Filgrastim should be discontinued and appropriate treatment given in these cases.</p><p>&nbsp;</p><p><em>Glomerulonephritis</em></p><p><em>&nbsp;</em></p><p>Glomerulonephritis has been reported in patients receiving filgrastim or pegfilgrastim. Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim or pegfilgrastim. Urinalysis monitoring is recommended.</p><p>&nbsp;</p><p><em>Capillary leak syndrome</em></p><p><em>&nbsp;</em></p><p>Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported after granulocyte colony-stimulating factor administration and is characterised by hypotension, hypoalbuminaemia, oedema and hemoconcentration. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care (see section 4.8).</p><p>&nbsp;</p><p><em>Splenomegaly and Splenic rupture</em></p><p><em>&nbsp;</em></p><p>Generally asymptomatic cases of splenomegaly and cases of splenic rupture have been reported in patients and normal donors following administration of filgrastim. Some cases of splenic rupture were fatal. Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal pain or shoulder tip pain. Dose reductions of filgrastim have been noted to slow or stop the progression of splenic enlargement in patients with severe chronic neutropenia, and in 3% of patients a splenectomy was required.</p><p>&nbsp;</p><p><em>Malignant cell growth</em></p><p><em>&nbsp;</em></p><p>G-CSF can promote growth of myeloid cells <em>in vitro </em>and similar effects may be seen on some non- myeloid cells <em>in vitro</em>.</p><p>&nbsp;</p><p><em>Myelodysplastic syndrome or Chronic myeloid leukemia</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome, or chronic myelogenous leukaemia have not been established. Filgrastim is not indicated for use in these conditions. Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukaemia from acute myeloid leukaemia.</p><p>&nbsp;</p><p><em>Acute myeloid leukaemia</em></p><p><em>&nbsp;</em></p><p>In view of limited safety and efficacy data in patients with secondary acute myelogenous leukaemia (AML), filgrastim should be administered with caution. The safety and efficacy of filgrastim administration in <em>de novo </em>AML patients aged &lt; 55 years with good cytogenetics [t(8;21), t(15;17), and inv(16)] have not been established.</p><p>&nbsp;</p><p><em>Thrombocytopenia</em></p><p><em>&nbsp;</em></p><p>Thrombocytopenia has been reported in patients receiving filgrastim. Platelet counts should be monitored closely, especially during the first few weeks of filgrastim therapy. Consideration should be given to temporary discontinuation or dose reduction of filgrastim in patients with severe chronic neutropenia who develop thrombocytopenia (platelet count &lt; 100&nbsp; x 109/l).</p><p>&nbsp;</p><p><em>Leukocytosis</em></p><p><em>&nbsp;</em></p><p>White blood cell counts of 100 x 109/l or greater have been observed in less than 5% of cancer patients receiving filgrastim at doses above 0.3 MU/kg/day (3 &mu;g/kg/day). No undesirable effects directly attributable to this degree of leukocytosis have been reported. However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy. If leukocyte counts exceed 50 x 109/l after the expected nadir, filgrastim should be discontinued immediately. When administered for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/l.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p><em>&nbsp;</em></p><p>As with all therapeutic proteins, there is a potential for immunogenicity. Rates of generation of antibodies against filgrastim is generally low. Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.</p><p>&nbsp;</p><p><u>Special warning and precautions associated with co-morbidities</u></p><p>&nbsp;</p><p><em>Special precautions in sickle cell trait and sickle cell disease</em></p><p><em>&nbsp;</em></p><p>Sickle cell crises, in some cases fatal, have been reported with the use of filgrastim in patients with sickle cell trait or sickle cell disease. Physicians should use caution when prescribing filgrastim in patients with sickle cell trait or sickle cell disease.</p><p>&nbsp;</p><p><em>Osteoporosis</em></p><p><em>&nbsp;</em></p><p>Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months.</p><p>&nbsp;</p><p><u>Special precautions in cancer patients</u></p><p>&nbsp;</p><p>Filgrastim should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.</p><p>&nbsp;</p><p><em>Risks associated with increased doses of chemotherapy</em></p><p><em>&nbsp;</em></p><p>Special caution should be used when treating patients with high-dose chemotherapy because improved tumour outcome has not been demonstrated and intensified doses of chemotherapeutic agents may lead to increased toxicities including cardiac, pulmonary, neurologic, and dermatologic effects (please refer to the prescribing information of the specific chemotherapy agents used).</p><p>&nbsp;</p><p><em>Effect of chemotherapy on erythrocytes and thrombocytes</em></p><p><em>&nbsp;</em></p><p>Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy. Because of the potential of receiving higher doses of chemotherapy (e.g. full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia. Regular monitoring of platelet count and haematocrit is recommended. Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.</p><p>&nbsp;</p><p>The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.</p><p>&nbsp;</p><p><em>Other special precautions</em></p><p><em>&nbsp;</em></p><p>The effects of filgrastim in patients with substantially reduced myeloid progenitors have not been studied. Filgrastim acts primarily on neutrophil precursors to exert its effect in elevating neutrophil counts. Therefore, in patients with reduced precursors, neutrophil response may be diminished (such as those treated with extensive radiotherapy or chemotherapy, or those with bone marrow infiltration by tumour).</p><p>&nbsp;</p><p>Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by transplantation.</p><p>&nbsp;</p><p>There have been reports of Graft versus Host Disease (GvHD) and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.8 and 5.1).</p><p>&nbsp;</p><p>Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient abnormal bone scans. This should be considered when interpreting bone- imaging results.</p><p>&nbsp;</p><p>Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. The symptoms experienced included fever, abdominal pain, malaise, back pain and inflammatory markers (e.g. C-reactive protein and white blood cell count) were raised. In most cases aortitis was diagnosed by CT scan and generally resolved after withdrawal of G-CSF. See also section 4.8.</p><p>&nbsp;</p><p><u>Special precautions in patients undergoing PBPC mobilisation</u></p><p>&nbsp;</p><p><em>Mobilisation</em></p><p><em>&nbsp;</em></p><p>There are no prospectively randomised comparisons of the two recommended mobilisation methods (Filgrastim alone, or in combination with myelosuppressive chemotherapy) within the same patient population. The degree of variation between individual patients and between laboratory assays of CD34+ cells mean that direct comparison between different studies is difficult. It is therefore difficult to recommend an optimum method. The choice of mobilisation method should be considered in relation to the overall objectives of treatment for an individual patient.</p><p>&nbsp;</p><p><em>Prior exposure to cytotoxic agents</em></p><p><em>&nbsp;</em></p><p>Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (&ge; 2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.</p><p>&nbsp;</p><p>Some cytotoxic agents exhibit particular toxicities to the haematopoietic progenitor pool and may adversely affect progenitor mobilisation. Agents such as melphalan, carmustine (BCNU) and carboplatin, when administered over prolonged periods prior to attempts at progenitor mobilisation may reduce progenitor yield. However, the administration of melphalan, carboplatin or BCNU together with filgrastim has been shown to be effective for progenitor mobilisation. When a PBPC transplantation is envisaged it is advisable to plan the stem cell mobilisation procedure early in the treatment course of the patient. Particular attention should be paid to the number of progenitors mobilised in such patients before the administration of high-dose chemotherapy. If yields are inadequate, as measured by the criteria above, alternative forms of treatment not requiring progenitor support should be considered.</p><p>&nbsp;</p><p><em>Assessment of progenitor cell yields</em></p><p><em>&nbsp;</em></p><p>In assessing the number of progenitor cells harvested in patients treated with filgrastim, particular attention should be paid to the method of quantitation. The results of flow cytometric analysis of CD34+ cell numbers vary depending on the precise methodology used and, recommendations of numbers based on studies in other laboratories need to be interpreted with caution.</p><p>&nbsp;</p><p>Statistical analysis of the relationship between the number of CD34+ cells re-infused and the rate of platelet recovery after high-dose chemotherapy indicates a complex but continuous relationship.</p><p>&nbsp;</p><p>The recommendation of a minimum yield of &ge; 2.0 x 106 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution. Yields in excess of this appear to correlate with more rapid recovery, those below with slower recovery.</p><p>&nbsp;</p><p><u>Special precautions in normal donors undergoing PBPC mobilisation</u></p><p>&nbsp;</p><p>Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.</p><p>&nbsp;</p><p>PBPC mobilisation should be considered only in donors who meet normal clinical and laboratory eligibility criteria for stem cell donation with special attention to haematological values and infectious disease.</p><p>&nbsp;</p><p>The safety and efficacy of filgrastim have not been assessed in normal donors &lt; 16 years or &gt; 60 years.</p><p>&nbsp;</p><p>Transient thrombocytopenia (platelets &lt; 100 x 109/l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied. Among these, two cases of platelets</p><p>&lt; 50 x 109/l were reported and attributed to the leukapheresis procedure.</p><p>&nbsp;</p><p>If more than one leukapheresis is required, particular attention should be paid to donors with platelets &lt; 100 x 109/l prior to leukapheresis; in general apheresis should not be performed if platelets &lt; 75 x 109/l.</p><p>&nbsp;</p><p>Leukapheresis should not be performed in donors who are anticoagulated or who have known defects in haemostasis.</p><p>&nbsp;</p><p>Donors who receive G-CSFs for PBPC mobilisation should be monitored until haematological indices return to normal.</p><p>&nbsp;</p><p>Transient cytogenetic abnormalities have been observed in normal donors following G-CSF use. The significance of these changes is unknown. Nevertheless, a risk of promotion of a malignant myeloid clone cannot be excluded. It is recommended that the apheresis centre perform a systematic record and tracking of the stem cell donors for at least 10 years to ensure monitoring of long-term safety.</p><p>&nbsp;</p><p><u>Special precautions in recipients of allogeneic PBPCs mobilised with filgrastim</u></p><p>&nbsp;</p><p>Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic GvHD when compared with bone marrow transplantation.</p><p>&nbsp;</p><p><u>Special precautions in SCN patients</u></p><p>&nbsp;</p><p>Filgrastim should not be administered to patients with severe congenital neutropenia who develop leukaemia or have evidence of leukaemic evolution.</p><p>&nbsp;</p><p><em>Blood cell counts</em></p><p><em>&nbsp;</em></p><p>Other blood cell changes occur, including anaemia and transient increases in myeloid progenitors, which require close monitoring of cell counts.</p><p>&nbsp;</p><p><em>Transformation to leukaemia or myelodysplastic syndrome</em></p><p><em>&nbsp;</em></p><p>Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia, and myeloid leukaemia. Complete blood cell counts with differential and platelet counts, and an evaluation of bone marrow morphology and karyotype should be performed prior to treatment.</p><p>&nbsp;</p><p>There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim. This observation has only been made in patients with congenital neutropenia. MDS and leukaemias are natural complications of the disease and are of uncertain relation to filgrastim therapy. A subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation. It is currently unclear whether long-term treatment of patients with SCN will predispose patients to cytogenetic abnormalities, MDS or leukaemic transformation. It is recommended to perform morphologic and cytogenetic bone marrow examinations in patients at regular intervals (approximately every 12 months).</p><p>&nbsp;</p><p><em>Other special precautions</em></p><p><em>&nbsp;</em></p><p>Causes of transient neutropenia, such as viral infections should be excluded.</p><p>&nbsp;</p><p>Haematuria was common and proteinuria occurred in a small number of patients. Regular urinalysis should be performed to monitor these events.</p><p>&nbsp;</p><p>The safety and efficacy in neonates and patients with autoimmune neutropenia have not been established.</p><p>&nbsp;</p><p><u>Special precautions in patients with HIV infection</u></p><p>&nbsp;</p><p><em>Blood cell counts</em></p><p><em>&nbsp;</em></p><p>Absolute neutrophil count (ANC) should be monitored closely, especially during the first few weeks of filgrastim therapy. Some patients may respond very rapidly and with a considerable increase in neutrophil count to the initial dose of filgrastim. It is recommended that the ANC is measured daily for the first 2 - 3 days of filgrastim administration. Thereafter, it is recommended that the ANC is measured at least twice per week for the first 2 weeks and subsequently once per week or once every</p><p>&nbsp;</p><p>other week during maintenance therapy. During intermittent dosing with 30 MU/day (300 &mu;g/day) of filgrastim, there can be wide fluctuations in the patient&#39;s ANC over time. In order to determine a patient&#39;s trough or nadir ANC, it is recommended that blood samples are taken for ANC measurement immediately prior to any scheduled dosing with filgrastim.</p><p>&nbsp;</p><p><em>Risk associated with increased doses of myelosuppressive medicinal products</em></p><p><em>&nbsp;</em></p><p>Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive treatments. As a result of the potential to receive higher doses or a greater number of these medicinal products with filgrastim therapy, the patient may be at higher risk of developing thrombocytopenia and anaemia. Regular monitoring of blood counts is recommended (see above).</p><p>&nbsp;</p><p><em>Infections and malignancies causing myelosuppression</em></p><p><em>&nbsp;</em></p><p>Neutropenia may be due to bone marrow-infiltrating opportunistic infections such as <em>Mycobacterium avium </em>complex or malignancies such as lymphoma. In patients with known bone marrow infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia. The effects of filgrastim on neutropenia due to bone marrow-infiltrating infection or malignancy have not been well established.</p><p>&nbsp;</p><p><u>All patients</u></p><p>&nbsp;</p><p><em>Latex-sensitive individuals</em></p><p><em>&nbsp;</em></p><p>The removable needle cap of this pre-filled syringe contains a derivative of natural rubber latex. No natural rubber latex has to date been detected in the removable needle cap. Nevertheless, the use of Zarzio solution for injection in pre-filled syringe in latex-sensitive individuals has not been studied and thus there is a potential risk for hypersensitivity reactions which cannot be completely ruled out.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>Zarzio contains sorbitol (E420). Patients with hereditary fructose intolerance (HFI) must not be given this medicine unless strictly necessary.</p><p>&nbsp;</p><p>Babies and young children (below 2 years of age) may not yet be diagnosed with hereditary fructose intolerance (HFI). Medicines (containing sorbitol/fructose) given intravenously may be life- threatening and should be contraindicated in this population unless there is an overwhelming clinical need and no alternatives are available.</p><p>&nbsp;</p><p>A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product.</p><p>In order to improve the traceability of granulocyte-colony stimulating factors (G-CSFs), the trade name of the administered product should be clearly recorded in the patient file.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of filgrastim given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, the use of filgrastim is not recommended in the period from 24 hours before to 24 hours after chemotherapy. Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-fluorouracil indicates that the severity of neutropenia may be exacerbated.</p><p>&nbsp;</p><p>Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical trials.</p><p>Since lithium promotes the release of neutrophils, lithium is likely to potentiate the effect of filgrastim. Although this interaction has not been formally investigated, there is no evidence that such an interaction is harmful.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of filgrastim in pregnant women. Studies in animals have shown reproductive toxicity. An increased incidence of embryo-loss has been observed in rabbits at high multiples of the clinical exposure and in the presence of maternal toxicity (see section 5.3). There are reports in the literature where the transplacental passage of filgrastim in pregnant women has been demonstrated.</p><p>&nbsp;</p><p>Zarzio is not recommended during pregnancy. <u>Breast-feeding</u></p><p>It is unknown whether filgrastim/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zarzio therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Filgrastim did not affect reproductive performance or fertility in male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim may have a minor influence on the ability to drive and use machines. Dizziness may occur following the administration of filgrastim (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea. In clinical trials in cancer patients musculoskeletal pain was mild or moderate in 10%, and severe in 3% of patients.</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>The data in the tables below describe adverse reactions reported from clinical trials and spontaneous reporting. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge; 1/100 to</strong></p><p><strong>&lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sepsis Bronchitis</p><p>Upper respiratory tract infection Urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Thrombocyto- penia Anaemiae</p></td><td style="vertical-align:top"><p>Splenomegalya Haemoglobin decreasede</p></td><td style="vertical-align:top"><p>Leukocytosisa</p></td><td style="vertical-align:top"><p>Splenic rupturea Sickle cell anaemia with crisis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune sys- tem disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity Drug hypersensitivitya Graft versus host diseaseb</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased Appetitee Blood lactate dehydrogenase increased</p></td><td style="vertical-align:top"><p>Hyperuricaemia Blood uric acid increased</p></td><td style="vertical-align:top"><p>Blood glucose decreased Pseudogouta (Chondrocal- cinosis Pyro- phosphate) Fluid volume disturbances</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headachea</p></td><td style="vertical-align:top"><p>Dizziness Hypoaesthesia Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension Hypotension</p></td><td style="vertical-align:top"><p>Veno-occlusive diseased</p></td><td style="vertical-align:top"><p>Aortitis Capillary leak syndromea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge; 1/100 to</strong></p><p><strong>&lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemoptysis Dyspnoea Cougha Oropharyngeal paina, e Epistaxis</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndromea Respiratory failurea Pulmonary oedemaa Pulmonary haemorrhage Interstitial lung diseasea</p><p>Lung infiltrationa Hypoxia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointesti- nal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoeaa, e Vomitinga, e Nauseaa</p></td><td style="vertical-align:top"><p>Oral pain Constipatione</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatomegaly Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Aspartate ami- notransferase increased Gamma- glutamyl transferase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Alopeciaa</p></td><td style="vertical-align:top"><p>Rasha Erythema</p></td><td style="vertical-align:top"><p>Maculopapular rash</p></td><td style="vertical-align:top"><p>Cutaneous vasculitisa Sweets syndrome (acute febrile neutrophilic dermatosis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskele- tal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Musculoskele- tal painc</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>Bone density decreased Exacerbation of rheumatoid arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria Haematuria</p></td><td style="vertical-align:top"><p>Proteinuria</p></td><td style="vertical-align:top"><p>Glomerulo- nephritis Urine abnormality</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administra- tion site conditions</strong></p></td><td style="vertical-align:top"><p>Fatiguea Mucosal inflammationa Pyrexia</p></td><td style="vertical-align:top"><p>Chest paina Paina Astheniaa Malaisee Oedema peripherale</p></td><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:67.7pt;margin-top:-116pt;width:460.35pt;
 height:121.2pt;z-index:251609600;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:text' o:allowincell="f" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge; 1/100 to</strong></p><p><strong>&lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transfusion reactione</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>a See section c (Description of selected adverse reactions)</p><p>&nbsp;</p><p>b There have been reports of GvHD and fatalities in patients after allogeneic bone marrow transplantation (see section c)</p><p>c Includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain</p><p>d Cases were observed in the post-marketing setting in patients undergoing bone marrow transplant or</p><p>PBPC mobilisation</p><p>e Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy</p><p>&nbsp;</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p><em>&nbsp;</em></p><p>Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post marketing experience. Overall, reports were more common after IV administration. In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.</p><p>&nbsp;</p><p><em>Pulmonary adverse events</em></p><p><em>&nbsp;</em></p><p>In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4).</p><p>&nbsp;</p><p><em>Splenomegaly and Splenic rupture</em></p><p><em>&nbsp;</em></p><p>Cases of splenomegaly and splenic rupture have been reported following administration of filgrastim. Some cases of splenic rupture were fatal (see section 4.4).</p><p>&nbsp;</p><p><em>Capillary leak syndrome</em></p><p><em>&nbsp;</em></p><p>Cases of capillary leak syndrome have been reported with granulocyte colony-stimulating factor use. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).</p><p>&nbsp;</p><p><em>Cutaneous vasculitis</em></p><p><em>&nbsp;</em></p><p>Cutaneous vasculitis has been reported in patients treated with filgrastim. The mechanism of vasculitis in patients receiving filgrastim is unknown. During long term use cutaneous vasculitis has been reported in 2% of SCN patients.</p><p>&nbsp;</p><p><em>Leukocytosis</em></p><p><em>&nbsp;</em></p><p>Leukocytosis (WBC &gt; 50 x 109/l) was observed in 41% of normal donors and transient thrombocytopenia (platelets &lt; 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).</p><p>&nbsp;</p><p><em>Sweets syndrome</em></p><p><em>&nbsp;</em></p><p>Cases of Sweets syndrome (acute febrile neutrophilic dermatosis) have been reported in patients treated with filgrastim.</p><p>&nbsp;</p><p><em>Pseudogout (chondrocalcinosis pyrophosphate)</em></p><p><em>&nbsp;</em></p><p>Pseudogout (chondrocalcinosis pyrophosphate) has been reported in patients with cancer treated with filgrastim.</p><p>&nbsp;</p><p><em>GvHD</em></p><p><em>&nbsp;</em></p><p>There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.4 and 5.1).</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Paediatric population</u></p><p>&nbsp;</p><p>Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy, suggesting no age-related differences in the pharmacokinetics of filgrastim. The only consistently reported adverse event was musculoskeletal pain&sbquo; which is no different from the experience in the adult population.</p><p>&nbsp;</p><p>There is insufficient data to further evaluate filgrastim use in paediatric subjects.</p><p>&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other special populations</u></p><p>&nbsp;</p><p><em>Geriatric use</em></p><p><em>&nbsp;</em></p><p>No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult (&gt; 18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients. There is insufficient data to evaluate filgrastim use in geriatric subjects for other approved filgrastim indications.</p><p>&nbsp;</p><p><em>Paediatric SCN patients</em></p><p><em>&nbsp;</em></p><p>Cases of decreased bone density and osteoporosis have been reported in paediatric patients with severe chronic neutropenia receiving chronic treatment with filgrastim.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1027"
 style='position:absolute;left:0;text-align:left;margin-left:108.95pt;
 margin-top:54.15pt;width:54pt;height:1pt;z-index:-251705856;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="1080,20" o:allowincell="f" path="m,hhl1079,e" filled="f"
 strokecolor="blue" strokeweight=".16931mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="73" height="1" src="file:///C:/Users/abulase1/AppData/Local/Temp/4/msohtmlclip1/01/clip_image001.png" />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of filgrastim overdosage have not been established. Discontinuation of filgrastim therapy usually results in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunostimulants, colony stimulating factors, ATC Code: L03AA02</p><p>&nbsp;</p><p>Zarzio is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.</p><p>&nbsp;</p><p>Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. Zarzio containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes. In some SCN patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dose-dependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 - 2 days, and to normal levels within 1 - 7 days.</p><p>&nbsp;</p><p>Use of filgrastim in patients undergoing cytotoxic chemotherapy leads to significant reductions in the incidence, severity and duration of neutropenia and febrile neutropenia. Treatment with filgrastim significantly reduces the duration of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation. The incidence of fever and documented infections were not reduced in either setting. The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation.</p><p>&nbsp;</p><p>Use of filgrastim, either alone, or after chemotherapy, mobilises haematopoietic progenitor cells into the peripheral blood. These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of, or in addition to bone marrow transplantation. Infusion of PBPC accelerates haematopoietic recovery reducing the duration of risk for haemorrhagic complications and the need for platelet transfusions.</p><p>&nbsp;</p><p>Recipients of allogeneic PBPCs mobilised with filgrastim experienced significantly more rapid haematological recovery, leading to a significant decrease in time to unsupported platelet recovery when compared with allogeneic bone marrow transplantation.</p><p>&nbsp;</p><p>One retrospective European study evaluating the use of G-CSF after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of GvHD, treatment related mortality (TRM) and mortality when G-CSF was administered. In a separate retrospective international study in patients with acute and chronic myelogenous leukaemias, no effect on the risk of GvHD, TRM and mortality was seen. A meta-analysis of allogeneic transplant studies, including the results of nine prospective randomized trials, eight retrospective studies and one case-controlled study, did not detect an effect on the risks of acute GvHD, chronic GvHD or early treatment-related mortality.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Relative Risk (95% CI) of GvHD and TRM</strong></p><p><strong>Following treatment with G-CSF after bone marrow transplantation</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Publication</strong></p></td><td style="vertical-align:top"><p><strong>Period of Study</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Acute Grade II - IV GvHD</strong></p></td><td style="vertical-align:top"><p><strong>Chronic GvHD</strong></p></td><td style="vertical-align:top"><p><strong>TRM</strong></p></td></tr><tr><td style="vertical-align:top"><p>Meta-Analysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>1.02</p></td><td style="vertical-align:top"><p>0.70</p></td></tr><tr><td style="vertical-align:top"><p>(2003)</p></td><td style="vertical-align:top"><p>1986 - 2001a</p></td><td style="vertical-align:top"><p>1198</p></td><td style="vertical-align:top"><p>(0.87, 1.33)</p></td><td style="vertical-align:top"><p>(0.82, 1.26)</p></td><td style="vertical-align:top"><p>(0.38, 1.31)</p></td></tr><tr><td style="vertical-align:top"><p>European</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Retrospective</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.33</p></td><td style="vertical-align:top"><p>1.29</p></td><td style="vertical-align:top"><p>1.73</p></td></tr><tr><td style="vertical-align:top"><p>Study (2004)</p></td><td style="vertical-align:top"><p>1992 - 2002b</p></td><td style="vertical-align:top"><p>1789</p></td><td style="vertical-align:top"><p>(1.08, 1.64)</p></td><td style="vertical-align:top"><p>(1.02, 1.61)</p></td><td style="vertical-align:top"><p>(1.30, 2.32)</p></td></tr><tr><td style="vertical-align:top"><p>International</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Retrospective</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.11</p></td><td style="vertical-align:top"><p>1.10</p></td><td style="vertical-align:top"><p>1.26</p></td></tr><tr><td style="vertical-align:top"><p>Study (2006)</p></td><td style="vertical-align:top"><p>1995 - 2000b</p></td><td style="vertical-align:top"><p>2110</p></td><td style="vertical-align:top"><p>(0.86, 1.42)</p></td><td style="vertical-align:top"><p>(0.86, 1.39)</p></td><td style="vertical-align:top"><p>(0.95, 1.67)</p></td></tr></tbody></table><p>&nbsp;</p><p>a Analysis includes studies involving BM transplant during this period; some studies used GM-CSF</p><p>b Analysis includes patients receiving BM transplant during this period</p><p>&nbsp;</p><p><em>Use of filgrastim for the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation</em></p><p>In normal donors, a 1 MU/kg/day (10 &mu;g/kg/day) dose administered subcutaneously for 4 - 5 consecutive days allows a collection of &ge; 4 x 106 CD34+ cells/kg recipient body weight in the majority of the donors after two leukaphereses.</p><p>&nbsp;</p><p>Use of filgrastim in patients, children or adults, with SCN (severe congenital, cyclic, and idiopathic neutropenia) induces a sustained increase in ANCs in peripheral blood and a reduction of infection and related events.</p><p>&nbsp;</p><p>Use of filgrastim in patients with HIV infection maintains normal neutrophil counts to allow scheduled dosing of antiviral and/or other myelosuppressive medication. There is no evidence that patients with HIV infection treated with filgrastim show an increase in HIV replication.</p><p>&nbsp;</p><p>As with other haematopoietic growth factors, G-CSF has shown <em>in vitro </em>stimulating properties on human endothelial cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Randomised, double-blind, single and multiple dose, crossover studies in 204 healthy volunteers showed that the pharmacokinetic profile of Zarzio was comparable to that of the reference product after subcutaneous and intravenous administration.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>A single subcutaneous dose of 0.5 MU/kg (5 &micro;g/kg) resulted in maximum serum concentrations after a tmax of 4.5 &plusmn; 0.9 hours (mean &plusmn; SD).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The volume of distribution in blood is approximately 150 ml/kg. Following subcutaneous administration of recommended doses, serum concentrations were maintained above 10 ng/ml for 8 - 16 hours. There is a positive linear correlation between the dose and the serum concentration of filgrastim, whether administered intravenously or subcutaneously.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The median serum elimination half-life (t1/2) of filgrastim after single subcutaneous doses ranged from</p><p>2.7 hours (1.0 MU/kg, 10 &micro;g/kg) to 5.7 hours (0.25 MU/kg, 2.5 &micro;g/kg) and was prolonged after 7 days of dosing to 8.5 - 14 hours, respectively.</p><p>Continuous infusion with filgrastim over a period of up to 28 days, in patients recovering from autologous bone-marrow transplantation, resulted in no evidence of drug accumulation and comparable elimination half-lives.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim was studied in repeated dose toxicity studies up to 1 year in duration which revealed changes attributable to the expected pharmacological actions including increases in leukocytes, myeloid hyperplasia in bone marrow, extramedullary granulopoiesis and splenic enlargement. These changes all reversed after discontinuation of treatment.</p><p>&nbsp;</p><p>Effects of filgrastim on prenatal development have been studied in rats and rabbits. Intravenous (80 &micro;g/kg/day) administration of filgrastim to rabbits during the period of organogenesis was&nbsp;maternally toxic and increased spontaneous abortion, post-implantation loss, and decreased mean live litter size and foetal weight were observed.</p><p>&nbsp;</p><p>Based on reported data for another filgrastim product similar to the reference filgrastim product, comparable findings plus increased foetal malformations were observed at 100 &micro;g/kg/day, a maternally toxic dose which corresponded to a systemic exposure of approximately 50 &ndash; 90 times the exposures observed in patients treated with the clinical dose of 5 &micro;g/kg/day. The observed adverse effect level for embryo-foetal toxicity in this study was 10 &micro;g/kg/day, which corresponded to a systemic exposure of approximately 3 &ndash; 5 times the exposures observed in patients treated with the clinical dose.</p><p>&nbsp;</p><p>In pregnant rats, no maternal or foetal toxicity was observed at doses up to 575 &micro;g/kg/day. Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (&ge;20 &micro;g/kg/day) and slightly reduced survival rate</p><p>(100 &micro;g/kg/day).</p><p>&nbsp;</p><p>Filgrastim had no observed effect on the fertility of male or female rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glutamic acid</p><p>Sorbitol (E420)</p><p>Polysorbate 80</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zarzio must not be diluted with sodium chloride solution.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>Diluted filgrastim may be adsorbed to glass and plastic materials, unless it is diluted in glucose 50 mg/ml (5%) solution (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.


After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light.</p><p>Within its shelf-life and for the purpose of ambulatory use, the patient may remove the product from the refrigerator and store it at room temperature (not above 25&deg;C) for one single period of up to 72 hours. At the end of this period, the product should not be put back in the refrigerator and should be disposed of.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pre-filled syringe (type I glass) with injection needle (stainless steel), with or without a needle safety guard, containing 0.5 ml solution.</p><p>&nbsp;</p><p>Pack sizes of 1, 3, 5 or 10 pre-filled syringes.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution should be visually inspected prior to use. Only clear solutions without particles should be used.</p><p>&nbsp;</p><p>The inner part of the needle cap of the syringe may contain dry rubber (latex). Persons sensitive to latex should take special care with Zarzio (see section 4.4).</p><p>&nbsp;</p><p>Accidental exposure to freezing temperatures does not adversely affect the stability of filgrastim.</p><p>&nbsp;</p><p>Zarzio contains no preservative. In view of the possible risk of microbial contamination, Zarzio syringes are for single use only.</p><p>&nbsp;</p><p><u>Dilution prior to administration (optional)</u></p><p>&nbsp;</p><p>If required, Zarzio may be diluted in glucose 50 mg/ml (5%) solution.</p><p>&nbsp;</p><p>Dilution to a final concentration &lt; 0.2 MU/ml (2 &mu;g/ml) is not recommended at any time.</p><p>&nbsp;</p><p>For patients treated with filgrastim diluted to concentrations &lt; 1.5 MU/ml (15 &mu;g/ml), human serum albumin (HSA) should be added to a final concentration of 2 mg/ml.</p><p>&nbsp;</p><p>Example: In a final volume of 20 ml, total doses of filgrastim less than 30 MU (300 &mu;g) should be given with 0.2 ml of human serum albumin 200 mg/ml (20%) solution Ph. Eur. added.</p><p>&nbsp;</p><p>When diluted in glucose 50 mg/ml (5%) solution, filgrastim is compatible with glass and a variety of plastics including polyvinylchloride, polyolefin (a copolymer of polypropylene and polyethylene) and polypropylene.</p><p>&nbsp;</p><p><u>Using the pre-filled syringe with a needle safety guard</u></p><p>&nbsp;</p><p>The needle safety guard covers the needle after injection to prevent needle stick injury. This does not affect normal operation of the syringe. Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. While maintaining pressure on the plunger, remove the syringe from the patient. The needle safety guard will cover the needle when releasing the plunger.</p><p>&nbsp;</p><p><u>Using the pre-filled syringe without a needle safety guard</u></p><p>&nbsp;</p><p>Administer the dose as per standard protocol. <u>Disposal</u></p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH Biochemiestr. 10
6250 Kundl Austria


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MM/YYYY
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>